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The RNA Decapping Machinery is a Conserved Anti-Bunyaviral Restriction Factor
Abstract
Arthropod-borne viruses (arboviruses) are an important class of emerging pathogens that cause mortality
and morbidity worldwide. As obligate intracellular parasites with limited coding capacity, viruses must
hijack host factors to replicate while evading host detection. To date, no specific therapeutic interventions
exist for arboviruses and most lack FDA approved vaccines. This is in part due to a lack of understanding
of viral-host interactions. To identify host factors that impact infection, we performed a genome-wide
RNAi screen in Drosophila and identified 131 genes that affected infection of the mosquito-transmitted
bunyavirus Rift Valley Fever virus (RVFV). Dcp2, the catalytic component of the mRNA decapping
machinery, and two decapping activators, DDX6 and LSM7, were antiviral against disparate bunyaviruses
in both insect cells and adult flies. Bunyaviruses 5' cap their mRNAs by `cap-snatching' the 5' ends of
poorly defined host mRNAs. We found that RVFV cap-snatches the 5' ends of Dcp2 targeted mRNAs,
including cell cycle related genes. Loss of Dcp2 allows increased viral transcription, while ectopic
expression of Dcp2 impedes transcription. Furthermore, arresting cells in late S/early G2 led to increased
Dcp2 mRNA targets and increased RVFV replication. Therefore, RVFV competes for the Dcp2-accessible
mRNA pool, which is dynamically regulated and can present a bottleneck for viral replication.
I extended these studies to mammalian cells and I found that the two known human decapping enzymes,
DCP2 and NUDT16, restrict RVFV replication. Since depletion of either gene impacted replication, this
suggests that DCP2 and NUDT16 are non-redundant. In human cells, I found that RVFV predominately
cap-snatches from mRNAs associated with translation, and the stability of these mRNAs is regulated by
decapping; furthermore, instability of these mRNAs is triggered by RVFV infection. I hypothesize that
translationally-associated genes, including ribosomal protein mRNAs, are selectively degraded during this
response to limit translation to prevent viral replication. These data suggest that a particular functional
class of mRNAs (translation-associated) can be coordinately regulated at the level of mRNA stability by
decapping, and that this may be used as a mechanism by cells to selectively regulate gene expression.
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ABSTRACT

THE RNA DECAPPING MACHINERY IS A CONSERVED ANTI-BUNYAVIRAL
RESTRICTION FACTOR

Kaycie C. Hopkins
Sara Cherry

Arthropod-borne viruses (arboviruses) are an important class of emerging
pathogens that cause mortality and morbidity worldwide. As obligate intracellular
parasites with limited coding capacity, viruses must hijack host factors to replicate while
evading host detection. To date, no specific therapeutic interventions exist for
arboviruses and most lack FDA approved vaccines. This is in part due to a lack of
understanding of viral-host interactions. To identify host factors that impact infection, we
performed a genome-wide RNAi screen in Drosophila and identified 131 genes that
affected infection of the mosquito-transmitted bunyavirus Rift Valley Fever virus (RVFV).
Dcp2, the catalytic component of the mRNA decapping machinery, and two decapping
activators, DDX6 and LSM7, were antiviral against disparate bunyaviruses in both insect
cells and adult flies. Bunyaviruses 5’ cap their mRNAs by ‘cap-snatching’ the 5’ ends of
poorly defined host mRNAs. We found that RVFV cap-snatches the 5’ ends of Dcp2
targeted mRNAs, including cell cycle related genes. Loss of Dcp2 allows increased viral
transcription, while ectopic expression of Dcp2 impedes transcription. Furthermore,
arresting cells in late S/early G2 led to increased Dcp2 mRNA targets and increased
RVFV replication. Therefore, RVFV competes for the Dcp2-accessible mRNA pool,
which is dynamically regulated and can present a bottleneck for viral replication.
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I extended these studies to mammalian cells and I found that the two known
human decapping enzymes, DCP2 and NUDT16, restrict RVFV replication. Since
depletion of either gene impacted replication, this suggests that DCP2 and NUDT16 are
non-redundant. In human cells, I found that RVFV predominately cap-snatches from
mRNAs associated with translation, and the stability of these mRNAs is regulated by
decapping; furthermore, instability of these mRNAs is triggered by RVFV infection. I
hypothesize that translationally-associated genes, including ribosomal protein mRNAs,
are selectively degraded during this response to limit translation to prevent viral
replication. These data suggest that a particular functional class of mRNAs (translationassociated) can be coordinately regulated at the level of mRNA stability by decapping,
and that this may be used as a mechanism by cells to selectively regulate gene
expression.
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I. INTRODUCTION
1. Arthropod-borne viruses
Arthropod-borne viruses (arboviruses) are an emerging class of infectious
diseases worldwide. Due to the vector-borne nature of their life cycle, arboviral infections
present unique challenges to disease prevention and treatment. Climate change has
increased the range of many species of mosquitoes capable of transmitting these
infections, and introduction of nonnative arboviruses across the Atlantic has already
occurred in at least one instance (West Nile virus) (71, 96). The absence of therapeutics
or FDA approved vaccines for these diseases is driven in part by our lack of
understanding of their replication strategies and host interactions, thus necessitating
increased research.
Arboviruses are a major cause of human and vertebrate morbidity and mortality
globally. These viruses replicate in a vertebrate host in the wild (the reservoir), often a
small mammal, such as a rodent, causing limited to no pathology. Hematophagous
arthropods, such as ticks or mosquitoes, then bite these infected vertebrates and
become infected. The virus replicates to high titers while causing limited to no pathology
in the insect. The insect becomes infected for life, infecting vertebrate hosts upon blood
feeding. While this lifecycle often is limited in its pathology to both host (vertebrate) and
vector (arthropod) species, incidental infections of so called “dead-end” or “off-target”
hosts can occur; these infections are typically in livestock or humans, and do not result
in retransmission to another biting insect, due to limited serum viral titers (139). Unlike
arboviral reservoir species, incidental infections may result in severe pathology.
Three main classes of arboviruses exist: 1) Flaviviruses, such as Dengue and
West Nile virus; 2) Alphaviruses, such as Sindbis virus and Chickungunya virus; and 3)
Bunyaviruses, such as Rift Valley Fever virus (RVFV) and LaCrosse virus (LACV).
1

Interestingly, all arthropod viruses that are medically relevant to human health are
enveloped RNA viruses (140).

2. Bunyaviruses and their replication
Bunyaviruses are spherical, enveloped viruses, containing a tripartite negative
sense RNA genome. Within the virion, the genome bound by nucleocapsid (N) protein,
and the viral RNA dependent RNA polymerase (RdRp) L is also encapsidated (Figure
1.1). The viral envelope contains the glycoproteins, Gn and Gc, responsible for entry
(15, 113). In addition to these 4 proteins, bunyaviruses encode up to three nonstructural
proteins that are dispensable for infection in cell culture and are virulence factors (15,
54, 133).
The bunyaviral genome consists of three segments, Large (L), Medium (M) and
Small (S). The L segment encodes the viral RdRp (L), while the S segment encodes the
N protein and the non-structural NSs protein; some bunyaviruses (including RVFV)
encode their S segment genes in an ambisense fashion. The M segment encodes one
polyprotein that is processed into the glycoproteins (Gn and Gc), and depending on the
bunyavirus species there may also be up to two nonstructural protein (NSm1 and NSm2)
that are also processed through differential cleavage (Figure 1.1) (15).
As obligate intracellular parasites with a limited coding capacity, viruses must
utilize existing cellular pathways for their replication. Arboviruses in particular replicate in
disparate and evolutionarily distant hosts; as such, arboviruses provide a unique system
to probe deeply conserved cellular biological processes. Bunyaviral replication has 5
main steps: 1) entry; 2) mRNA transcription; 3) protein translation; 4) genomic RNA
replication; and 5) egress (Figure 1.2). Bunyaviruses bind to largely unknown receptors
and enter through endocytic pathways. Some are thought to enter through clathrin2

mediated endocytosis, while for others macropinocytosis has been shown to be
important. Uncoating and viral fusion with the membrane are pH dependent and require
endosomal acidification (45), but the exact requirements and pathways for bunyaviral
entry are poorly understood (80). Following entry, the viral genome is transcribed in the
cytosol by N and L into viral mRNA through a mechanism known as “cap-snatching,”
detailed below in Section 1.3. Transciptional termination is determined by a short (5-6 nt)
motif, and bunyaviral mRNAs are largely not polyadenylated (8). Some bunyaviral
mRNAs have been shown to have stem-loop structures at their 3’ ends that facilitate
translation and are thought to be similar to the stem-loop structure required for
replicating histone mRNA translation. However, this structure is not present in all
segments, which makes it unclear how those mRNAs are translated (8, 12).
Interestingly, translation of viral mRNAs occurs co-transcriptionally, whereby
translational elongation prevents premature mRNA transcriptional termination (7).
mRNAs synthesized from the S and L segments are translated on cytoplasmic
ribosomes, while M segment mRNA is translated by ribosomes associated with the
rough endoplasmic reticulum; M segment derived proteins mature in the golgi (55).
Genome replication occurs through the transcription of an antisense cRNA intermediate,
from which the genome is amplified. Genomic replication is thought to occur on Golgi
derived tube-like membrane invaginations (48). Following genome encapsidation by N,
assembly occurs at the golgi membrane, potentially through interactions between N and
the intracellular terminus of Gn or Gc (55). Virions bud into the golgi, where they utilize
the cell’s secretory pathway for release via exocytosis.

3. Cap-snatching as a mechanism of viral mRNA transcription

3

Eukaryotic mRNAs recruit ribosomes for translation and enhance their stability
using two structures: a 5’ cap encoded by a methylated guanosine attached in a 5’ to 5’
orientation via a triphosphate bond, and a 3’ polyadenosine tail. All viruses utilize host
ribosomes for translation and thus must recruit host ribosomes. Viruses that transcribe
their mRNA in the nucleus, such as Human Immunodeficiency virus (HIV), hijack the
cellular capping and polyadenylation pathways to make their mRNAs indistinguishable
from endogenous messages. Cytoplasmically replicating viruses have evolved diverse
mechanisms to recruit host ribosomes and to protect their 5’ and 3’ RNA ends from
degradation. First, some cytoplasmically replicating RNA viruses, such as Sindbis virus
(SINV) and Vesicular Stomatitis virus (VSV), use their RdRps to cap and polyadenylate
their mRNAs (2, 74). Second, some viruses, including the arthropod-transmitted
flaviviruses, lack poly-A tails, but use nonstructural proteins to create 5’ caps and recruit
ribosomes through use of internal ribosome entry sites (IRES), sequences that form
elaborate secondary structure to facilitate ribosome assembly (124). Third, negative
sense segmented RNA viruses have all evolved a mechanism of ‘cap-snatching,’ in
which the 5’ cap and a short sequence of a host mRNA is cleaved by the viral RdRp and
used as a primer to initiate transcription of viral mRNAs (50).
Segmented negative sense RNA viruses include the orthomyxoviruses, the
arenaviruses and the bunyaviruses. Best studied of these are the orthomyxoviruses, in
particular Influenza A virus, primarily due to its drastic impact on human health.
Orthomyxoviruses transcribe their mRNA in the nucleus and cap-snatch off of premRNAs that are not fully spliced (59, 102). Unlike Influenza, bunyaviruses and
arenaviruses transcribe their mRNAs in the cytoplasm and thus they must use a distinct
pool of host mRNAs. Bunyaviruses recognize 5’ caps of host mRNAs using specific
binding sites on the N protein, and their polymerase encodes endonuclease activity that
4

cleaves 10-18 nt downstream of the 5’ cap (17, 85, 100, 106, 116). This primer is then
used to initiate viral mRNA transcription (Figure 1.3). Therefore all bunyaviral mRNAs
have 10-18 nucleotides (nt) of nonviral origin at their 5’ end (116). The pool of
endogenous mRNAs that are snatched by bunyaviruses is not known; however data
from Mir et al. demonstrated that ectopically expressed mRNAs incorporate into viral
mRNAs, and that this incorporation is increased if a nonsense-mediated decay (NMD)
signal is introduced into the mRNA (83). This suggests that bunyaviral cap-snatching
may interact with the host RNA decay machinery, but it is unknown how this may occur.

4. Rift Valley Fever virus
Bunyaviruses are a large diverse group that is divided into 5 genera: rodenttransmitted hantaviruses (the only genus lacking an arthropod vector); plant-infecting
tospoviruses transmitted by thrips; tick-transmitted nairoviruses; mosquito-transmitted
orthobunyaviruses (e.g. La Crosse virus); and the phleboviruses, which are primarily
transmitted by biting flies, but some of which (e.g. Rift Valley Fever virus) are mosquitotransmitted (135). In the orthobunyavirus genus, La Crosse virus is endemic to the
United States and can cause severe pathology in the young, elderly and immune
susceptible, including encephalitis and death (52, 56). Hantaviruses, which are the only
genus of bunyaviruses transmitted through aerosolization of rodent exceta rather than
biting arthrpods, are highly fatal and cause severe pulmonary pathology in infected
humans; recent outbreaks of the hantavirus Sin Nombre virus in the United States have
caused fatalities (1). The emerging phlebovirus, Rift Valley Fever virus (RVFV) is
considered a select agent by the USDA and Human Health and Services and has been
considered to be a bioterrorist threat (140). RVFV typically causes self-limiting febrile
illness in humans, but it can cause fatal hemorrhagic or encephalitic disease in 1-3% of
5

patients and has high mortality rates among livestock (13, 101). Unlike most other
viruses in the phlebovirus genus, which are tick-transmitted, RVFV is transmitted by
mosquitoes. RVFV is endemic in Africa but has recently spread to the Arabian peninsula
(47); mosquito species elsewhere, including in the US, have been shown to be capable
of carrying and transmitting RVFV, highlighting the importance of this pathogen to
human health, both worldwide and domestically (47). Additionally, the natural vertebrate
reservoir of RVFV is unknown. Infection of humans occurs either by the bite of a
mosquito or through the handling of infected livestock (47). There are no commercially
available vaccines or specific treatments for RVFV. This is due in part to our lack of
understanding about the interplay between this virus and cellular host factors.

5. RNAi screening as a method to identify host-pathogen interactions
The advent of technology allowing for the artificial use of the RNA-interfence
(RNAi) pathway to target specific messages has opened the door for new approaches to
loss of function screening. High-throughput cell based screening technology has led to
an explosion of unbiased RNAi screening to identify host factors that pathogens subvert
or hijack. In addition to allowing for the identification of novel therapeutic targets, these
studies have also led to a greater understanding of cellular biology, including basic
cellular mechanisms of viral recognition and limiting factors for viral replication (29).
Drosophila provides an excellent model for unbiased RNAi screening for
conserved host factors impacting viral pathogens (34, 58, 88, 107, 108, 112). In addition
to their high efficiency of RNAi knockdown, their limited genomic redundancy as
compared to mammals allows for a greater chance of identifying potential targets based
on a single gene knockdown approach. Additionally, in tissue culture, there is no need to
transfect to perform RNAi on Drosophila cells, decreasing the rate of knockdown
6

variability and cost. Using Drosophila as a model also allows for ease in transitioning to
in vivo approaches for confirmation of screen hits, as comprehensive mutant and in vivo
RNAi lines are commercially available and have short generation time (27, 28, 33).
Technically, the long-term use of fruit flies as a model has also led to an exceptionally
well-annotated genome, and almost complete genomic coverage can be obtained
commercially for RNAi screening. Finally, Drosophila has been shown to share
conserved immune factors and pathways with higher organisms, including humans (e.g.
Toll) (72), and thus provides an excellent model for probing conserved interactions with
viral pathogens.

6. RNA degradation
The steady-state levels of RNAs are driven by two competing pathways:
biogenesis and decay. In Eukaryotes, mRNA stability and translation are intricately
linked by both cis and trans elements. At the 5’ end, the RNA cap protects against 5’ to
3’ decay by exonucleases and promotes translation. Likewise, at the 3’ end, the polyA
tail recruits Poly A Binding Protein (PABP), which prevents 3' to 5’ decay and promotes
translation (127). Furthermore, proteins bound to these elements promote RNA
circularization, which also facilitates translation initiation. Therefore, to degrade an
mRNA, these protective elements must be removed. Deadenylation is thought to be the
initial signal triggering most RNA turnover and is thought to be proceeded by or
concomitant to decreases in the rate of translation. Subsequently, RNAs can be
degraded from either end. The RNA exosome is a large complex that includes two
exonucleases and is the major 3’ to 5’ exonuclease in the cell. 5’ to 3’ decay first
requires the removal of the 5’ cap, and this step is rate limiting for decay. mRNA
decapping occurs on aberrant pools of mRNAs in the nucleus, as well as on
7

deadenylated mRNAs in the cytoplasm. Canonical mRNA decapping itself is catalyzed
by the NUDIX domain of DCP2, which cleaves the RNA cap, leaving an RNA moiety with
a 5’ monophosphate. This 5’ monophosphate is the substrate for processive degradation
by the 5’ to 3’ exonuclease XRN1 (Figure 1.4) (91). Recently, increasing complexity in
decapping has been described in mammals with the identification of NUDT16, another
NUDIX domain containing decapping enzyme with widespread tissue expression in mice
and humans (118). Initial reports suggest that these decappers have both redundant and
specific functions in specialized RNA decay pathways, such as RNA silencing, NMD
decay and AU-rich-element (ARE) mediated decay (76). Furthermore, activators of
decapping have been identified, including the human DEAD box RNA helicase
DDX6/Rck. Many of these proteins are RNA binding and inhibit translation; as translation
and decapping are competing steps, these activators tip the balance in favor of decay
(35, 46, 122). However, the exact mechanisms of decapping activation are unknown (94,
142).

7. Processing bodies
Processing (P) bodies are recently described (43) cytoplasmic aggregates of
RNPs that contain most of the RNA decay machinery. These RNP complexes are
endogenously present and are dynamically regulated; microscopically visible P bodies
fluctuate with various cellular stresses and conditions (42). P body granules are thought
to contain all of the RNA silencing, non-sense mediated decay and 5’ to 3’ RNA
degradation machinery (64, 114, 129). Unlike closely related stress granules, ribosomes
are absent from P body complexes (41). Changes in P body architecture have been
described following knockdown or overexpression of various components (42). Further,
visible punctae integrity is dependent not only on particular nucleating proteins, but also
8

on the endogenous RNAs in these complexes (42). Interestingly, while silencing and
decapping components are in P bodies, the presence of microscopically visible punctae
is not required for their activity (42). This suggests that while P body architecture may be
informative, it is not be physiologically required for some cellular activities occuring in P
bodies (42). Furthermore, some RNAs are thought to be stored in these structures, and
RNAs targeted to P bodies sometimes re-enter pools of translating mRNAs (4, 99). For
example, specialized cell types, including germ cells and neurons, have P body-like
structures that share many protein components with P bodies (97, 141). These RNP
granules are thought to be sites of mRNA storage and to allow for the control of mRNA
translation in a spatially and temporally regulated manner. Increasing electron
microscopy evidence also suggests that P bodies and specialized P body structures are
in close proximity with ribosomes (36, 141), although whether this close association
facilitates the return of P body mRNAs to translational pools or is the result of incoming
mRNAs being targeted for degradation is not clear.

8. Aim of present studies
Rift Valley Fever virus has shown the potential to spread as it has emerged;
originally isolated to Sub-Saharan Africa, RVFV has spread to cause outbreaks in Egypt
and the Saudi Arabian Peninsula in the last few decades. As mosquitoes throughout the
United States are permissive to infection, and since its impacts on human health and
livestock could be catastrophic, increasing our understanding of the molecular
mechanisms of RVFV replication is essential to the development of therapeutics and
vaccine strategies. Therefore, the work described in Chapter III aims to characterize the
host-pathogen interactions of RVFV using a cell-based genome-wide RNAi screen in
Drosophila. The goal of these studies is to identify host-pathogen interactions, especially
9

those that may be conserved among multiple hosts of RVFV infection, for potential
therapeutic intervention.
From the genome-wide RNAi screen in Chapter III, I found that three
components of the P-body-resident RNA decapping pathway were antiviral in
Drosophila. In Chapter III, I go on to characterize the mechanism by which the RNA
decapping enzyme Dcp2 restricts RVFV replication and find that this restriction is
bunyaviral specific and occurs at the level of cap-snatching. I demonstrate that RNA
decapping and cap-snatching are competing processes for the same pool of RNA
substrates, and that cap-snatching and decapping are spatially linked in P bodies. Using
sequencing strategies to examine the 5’ ends of viral mRNAs, I find that cap-snatching
occurs primarily on cell cycle related mRNAs in insects. In Chapter III, I also show that P
body morphology and the cell cycle are linked in insects, extending the findings of others
in humans to show that this is a deeply conserved process.
I next extended these studies to examine whether cap-snatching is a conserved
bottleneck for RVFV infection in humans. In Chapter IV, I demonstrate that either of the
characterized mRNA decappers in humans, DCP2 or NUDT16, is able to restrict RVFV
infection. Additionally in Chapter IV, I set out to characterize the pools of endogenous
mRNAs that are snatched by RVFV in humans; I find that RNAs related to translation are
predominantly snatched during infection and demonstrate both redundancy and
specificity of the decapping enzymes to degrade these RNA targets. Intriguingly, in
Chapter IV, I find that RVFV infection triggers loss of microscopically visible P bodies in
humans late in infection, which may be due to the activation of decapping as an antiviral
response to RVFV. Thus, these studies demonstrate that mRNA decapping has a deeply
conserved intersection with bunyaviral replication and provide insight into potential
therapeutic targets for bunyaviral treatment in multiple host organisms.
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Figure 1.1. Rift Valley Fever virus virion structure and coding strategy. Rift Valley Fever
virus virions are enveloped (dark red) and spherical and composed of four main structural
proteins: the glycoproteins Gc (orange) and Gn (peach) on the envelope surface, the
nucleocapsid (N) protein encapsidating the anti-sense viral genome (dark red circles), and the
viral polymerase (L), which facilitates viral transcription following viral entry (bright red wedges).
The viral genome is comprised of three anti-sense segments: Large (L), encoding the viral
polymerase; M, which encodes two nonstructural proteins (NSm1 and NSm2) and the
glycoproteins (Gn and Gc); and S, which encodes the nonstructural virulence factor NSs and the
nucleocapside protein N in an ambisense strategy.
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Figure 1.2. Bunyaviral entry, replication and assembly. Bunyaviruses enter cells by first
binding to largely unknown receptors (top left) that mediate endocytosis. Entry occurs in a pH
dependent fashion. Viral mRNA transcription occurs via a cap-snatching mechanism (middle left).
Viral mRNAs encoding the glycoproteins Gn and Gc are translated by ribosomes into the rough
endoplasmic reticulum (middle); these proteins then mature in the golgi. Other viral proteins are
translated in the cytoplasm and facilitate viral genomic replication (bottom left to right). Viral
genome is encapsidated by nucleocapsid protein and buds into the golgi (middle right). Finally,
fully assembled virions egress from the cell using cellular exocytosis pathways (top right).
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Figure 1.3. Bunyaviral cap-snatching. Host mRNA caps (blue) are recognized by the viral
nucleocapsid protein, which recruits the viral polymerase L. L cleaves 10-18nt downstream of the
5’ cap, yielding a snatched, capped oligomer and an RNA moiety with a 5’ monophosphate. L
transcribes the viral mRNA from the genomic RNA downstream of this primer. Completed viral
mRNAs have host derived 5’caps (blue) and lack poly-A tails; some viral mRNAs may have 3’
stem-loops that aid in viral translation (red).
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Figure 1.4. 5’ to 3’ mRNA decay in Eukaryotes. To initiate 5’ to 3’ RNA decay, cellular mRNAs
are deadenylated and then targeted to the canonical decapping enzyme, Dcp2, which resides in
Processing (P) bodies. Dcp2 cleaves the 5’ to 5’ triphosphate bond, removing the 7mG cap and
exposing a 5’ monophosphate. This monophosphate is the substrate for the processive 5’ to 3’
exonuclease XRN1.
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II. MATERIALS AND METHODS

1. Cells, Viruses, Antibodies and Reagents
Drosophila DL1 cells were grown and maintained as previously described (32).
Human U2OS cells were grown and maintained as previously described (88). VSVeGFP (gift from J. Rose) was grown in BHK cells as described (105). Sindbis/GFP (gift
from R. Hardy) was grown in C636 cells (21). DCV was grown and purified as described
(32). MP12 strain of RVFV was grown in Vero cells as described (45). Original strain of
LACV was prepared as described previously (66). Antibodies were obtained from the
following sources: anti-GFP (Invitrogen), anti-tubulin (Sigma), anti-DCV (32), anti-RVFV
N ID8 and anti-RVFV Gn 4D4 (gifts from R. Doms), anti-Rck (MBL), anti-Dcp1a
(Abcam), anti-beta Integrin (Abcam), and Alexa-488 conjugated Rabbit anti-Flag
(Invitrogen). Fluorescent secondary antibodies were obtained from Invitrogen, and HRPconjugated antibodies were obtained from Amersham. Additional chemicals were
obtained from Sigma.

2. RNAi
dsRNAs were generated as described (18). For RNAi, DL1 or Aag2 cells were
passaged into serum free media and plated into wells containing dsRNA. One hour later,
complete media was added and cells were incubated for three days.

3. siRNA
U2OS cells were seeded on 6 well plates in 2mL complete DMEM, then
transfected with the indicated siRNA using HiPerfect transfection reagent in OptiMEM at
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a final concentration of 20nM. Cells were incubated for three days to allow for
knockdown.

4. Viral Infections
Insects: Three days post-RNAi, cells were infected with the indicated viral
inoculum. VSV (MOI=0.01) and DCV (MOI=0.4) were processed at 24 hours post
infection. SIN (MOI=2.5) and RVFV (DL1-MOI=0.01, Aag-2-MOI=0.06) were
spinoculated at 1200 rpm for 2 hours and processed at 36 hours and 30 hours postinfection, respectively. For RNA collection, cells were infected with either RVFV
(MOI=0.1) or LACV (MOI=2.5), spinoculated for 2 hours at 1200rpm, and collected at
either 30 or 72 hours, respectively.
Human cells: Three days post-siRNA cells were infected with RVFV at an MOI of
1. Cells were processed at 18-22 hours post infection for all experiments unless
otherwise indicated.

5. Immunofluorescence
Cells were fixed, processed, imaged by automated microscopy and subject to
automated image analysis as described (107). For colocalization studies, z-stacks of 20
planes were taken at 63X, deconvolved and scored.

6. RNA analysis
Total RNA was extracted, northern blotted and quantified as previously described
(30). RT-qPCR was performed as previously described (143). Primer sequences are
described below in section 2.13.
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7. Cycloheximide treatment
Drosophila cells were treated with the indicated dsRNA and infected with RVFV.
28 hours post infection, cells were treated with 10µg/mL cycloheximide, and total RNA
was collected every 30 minutes.

8. 5’RACE and cloning
5’RACE was performed using the FirstChoice RLM-RACE kit from Ambion
according to the manufacturer’s instruction. RT-PCR was performed as described (143)
using primers specific for the 5’RACE adaptor (forward) and RVFV N transcript (reverse)
and gel purified (Qiagen) prior to ligation using TOPO TA cloning system (Invitrogen).
Sequences were blasted against the Drosophila genome; those that matched within 40
bp of the annotated 5’ end of a transcript and containing less than or equal to 1 end
mismatch were considered hits.

9. BOWTIE analysis of human 5’RACE sequences
Snatched sequences were mapped to the Hg19 genome with BOWTIE, using a
seed length of 12 and allowing zero mismatches. The resulting regions were intersected
with the coordinates of annotated human 5' UTRs, downloaded from UCSC (Hg19). The
5' UTRs were then manually inspected to verify the presence of the snatched sequence
near the transcriptional start site. If multiple matches were present, distance from the
annotated transcriptional start site was used to determine the more likely match.

10. Exonuclease Digest Assay
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10µg of total RNA was denatured at 95ºC for 2’, then either mock treated or
digested using Terminator Exonuclease (Epicentre) as per manufacturer’s instruction
and evaluated by northern blot.

11. Adult Fly Infections
Flies were obtained from the VDRC or Bloomington stock center. 4-7 day old flies
carrying UAS-Dcp2 IR (VDRC transformant: 22272) or control (w1118) were crossed to
hs-Gal4 and challenged and heat shocked every two days (RVFV) or maintained at 29°C
throughout the experiment (LACV) (32). Flies were monitored daily for mortality
(analyzed with a log rank test) or 15 flies per condition were processed at the indicated
time point post infection for RNA analysis as described (143).

12. Cap radiolabeling of mRNA
Uncapped mRNA was in vitro transcribed from pT GFP vector (83) using a T7
transcription system (Ambion T7 5x Megascript Kit) and then purified by precipitation.
RNA was capped using Vaccinia Virus Capping System (NEB) with P32 alpha-GTP
(Perkin Elmer) according to manufacturer’s instruction.

13. Oligonucleotide Sequences for Probes and RT-PCR

Dcp2 qPCR primers (Drosophila):
F 5’- CGCAAGGAGAAGCAGCAACAACTT-3’,
R 5’- TGACTGGCTGCTGTGGATTGTACT-3’

DDX6 qPCR primers (Drosophila):
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F 5’- TCGATTTCCCACGAATGGCAGAGA-3’,
R 5’- TCCGATGCAGATCAAACCGATCCT-3’

CG8878 qPCR primers (Drosophila):
F 5’- AGGCGCTATGAAGGTAAACCCACT-3',
R 5’- TATGCTCCTGGACAACCAAACCCT-3’

CG7580 qPCR primers (Drosophila):
F 5’- TCCAACGTCTTCATCGTTACTC-3',
R 5’- TTATTCGTCGTTCGCGTAGTC-3’

Jupiter qPCR primers (Drosophila):
F 5’- GCTACAAGGTCGTAGCCAAC-3',
R 5’-ACAGGCCCGACGAGTAG-3’

RP49 qPCR primers (Drosophila):
F 5’-AAGAAGCGCACCAAGCACTTCATC-3’,
R 5’-TCTGTTGTCGATACCCTTGGGCTT-3’

Dcp2 dsRNA primers (Drosophila):
F 5’-TAATACGACTCACTATAGGAGACCGGGTTCGATATCAC-3’,
R 5’- TAATACGACTCACTATAGGTCCCGCTCCCGTTCCA-3’

DDX6 dsRNA primers (Drosophila):
F 5’- TAATACGACTCACTATAGGCACTCCCGGACGAATATTAG-3’,
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R 5’- TAATACGACTCACTATAGGAGATTGCGACAGAGTCCTT-3’

Dcp2 dsRNA primers (Aedes):
F 5’- TAATACGACTCACTATAGGCAAACTGTCGGTTCCCACTT-3’,
R 5’- TAATACGACTCACTATAGGGCCATTCCTTTCTGTTTGGA-3’

DDX6 dsRNA primers (Aedes):
F 5’- TAATACGACTCACTATAGGCAGTACTACGCGTTCGTCCA-3’,
R 5’- TAATACGACTCACTATAGGGGCCAATTCTGTGCAGGTAG-3’

DCP2 qPCR primers (Human):
F 5’- TCCTCGAGAGGTGGAGAAA-3’
R 5’- GAGAGCCACAGCTTCAGTATAA-3’

NUDT16 qPCR primers (Human):
F 5’- GGTAGGCAGCCACTATCATTT-3’
R 5’- GCAGTCCCTGCAGCTATATT-3’

GAPDH qPCR primers (Human):
F 5’- ACCAAATCCGTTGACTCCGACCTT-3’
R 5’- TCGACAGTCAGCCGCATCTTCTTT-3’

5’RACE primers:

5’RACE adaptor outer primer:
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F 5’-GCTGATGGCGATGAATGAACACTG-3’

5’RACE adaptor inner primer: F
5’-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG-3’

Host mRNA-viral mRNA conjugate RT-qPCR primers:

MP12 N R: 5’-GGGCTTGTTGCCACGAGTTAGA-3’

MP12 N F: 5’-CAAGCAGTGGACCGCAATGAGA-3’

Drosophila His3 5’end Forward primer (with T7 linker):
5’- TAATACGACTCACTATAGGATTGTGTTTTC-3’

Drosophila CG8878 5’end Forward primer (with T7 linker):
5’- TAATACGACTCACTATAGGAAAAACTGCGTG -3’

Drosophila Jupiter 5’end Forward primer (with T7 linker):
5’-TAATACGACTCACTATAGGTTTAGCGGCTTAC-3’

Human HIS3 5’end Forward primer (with T7 linker):
5’- TAATACGACTCACTATAGGCTATGGCACG -3’
Human H2A 5’end Forward primer (with T7 linker):
5’- TAATACGACTCACTATAGGATGTCNGGACG-3’
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Human RPS3A 5’end Forward primer (with T7 linker):
5’-TAATACGACTCACTATAGGTCTGACCAGCACC-3’

Human RPL37A 5’end Forward primer (with T7 linker):
5’-TAATACGACTCACTATAGGCTTTCTGGGCTC-3’
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III. MRNA DECAPPING RESTRICTS BUNYAVIRAL REPLICATION BY LIMITING
THE POOLS OF DCP2-ACCESSIBLE TARGETS FOR CAP-SNATCHING IN
INSECTS1

1. Background
RNA stability is a key factor in the regulation of eukaryotic gene expression.
Within the RNA moiety, cis elements, including the 5’ 7mG cap and the 3’ poly-A tail,
play dual roles in protecting the mRNA from exonuclease-mediated degradation and
promoting translation. RNA degradation is both actively regulated and an essential part
of normal RNA turnover (127). Two strategies account for the majority of mRNA
turnover: 3’ to 5’ mediated decay via the exosome and 5’ to 3’ degradation by the
exonuclease Xrn1. Both strategies are dependent on loss of protective cis elements;
initial deadenylation of the polyA tail signals for both exosome-dependent targeting and
removal of the 5’ 7mG cap by the canonical decapping enzyme Dcp2 (127). Dcp2
cleavage of the cap exposes a 5’ monophosphate that is the substrate for Xrn1 (90).
Furthermore, perhaps as a regulatory mechanism, the RNA degradation machinery is
largely compartmentalized within the cytoplasm. The decapping machinery and the 5’ to
3’ exonuclease are localized to Processing (P) bodies (64, 115, 129). P bodies are
granules of ribonucleoproteins (RNPs), microscopically visible, and are dynamic in their
size and number. Additionally, P bodies act as storage depots; some RNAs targeted to
the P body are degraded, while others may be released (99). Thus the dynamic control
of mRNA stability and turnover can be regulated by P body biology. This is consistent
with the fact that cellular conditions, including stress and translational inhibition, alter the
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  This chapter is reprinted from Hopkins, K., L. McLane, T. Maqbool, B. Gordesky-Gold, and S.
Cherry. 2013. A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral
replication by limiting the pools of Dcp2-accessible targets for cap-snatching, Genes &
Development, with permission from Cold Spring Harbor Laboratory Press.
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visible morphology of P bodies within the cytoplasm (42). Interestingly, however,
microscopically visible P body punctae are dispensable for the function of multiple
mRNA decay pathways, suggesting that their structure is a marker for increased pools of
accumulating mRNAs (42).
As obligate intracellular pathogens with limited coding capacity, viral RNAs must
replicate to high levels and hijack the translation apparatus, while simultaneously
avoiding the host’s degradation machinery. Furthermore, RNA viruses must also
maintain stability of different RNA species, including the genome, antigenome and
mRNA. Viruses have evolved complex strategies to protect their 5’ ends from
exonucleases while facilitating translation. Some viruses that replicate in the nucleus
hijack the endogenous capping machinery (e.g., retroviruses), while viruses that
replicate in the cytoplasm cannot. To overcome this barrier, some cytoplasmic viruses
encode their own capping machinery and generate mRNAs that resemble endogenous
mRNAs (e.g., rhabdoviruses) (73). Other viruses protect the 5’ end from degradation by
covalently attaching a protein to the 5’ end that prevents targeting by exonucleases (e.g.,
picornaviruses). However, this prevents canonical translation, and thus these viruses
use internal ribosome entry sites to engage the translation machinery (110). Another
group of viruses “cap-snatch,” that is they steal the 5’ end of host mRNAs using a virallyencoded endonuclease, generating primers that are used by the viral RNA-dependent
RNA polymerase to generate viral mRNAs (51). The 5’ end of the viral mRNA is
therefore indistinguishable from endogenous mRNAs, and thus it is both protected from
degradation and able to recruit host ribosomes. All negative sense segmented RNA
viruses (orthomyxoviruses, arenaviruses and bunyaviruses) cap-snatch. Of these,
Influenza A virus, an orthomyxovirus, is the best studied and snatches the 5’ end of premRNAs in the nucleus (59, 102). Since bunyaviruses and arenaviruses replicate in the
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cytoplasm, they must use a distinct pool of mRNAs; however, while our mechanistic
understanding of bunyaviral cap-snatching is increasing (25, 85, 87, 106, 130, 131), little
is known about whether the host can combat this replication step or what pool of
endogenous mRNAs are being targeted for this process.
Bunyaviruses are an emerging group of medically and agriculturally important
viruses, many of which are insect-borne. Rift Valley Fever virus (RVFV) is a mosquitoborne emerging bunyavirus in Africa that can cause encephalitic or hemorrhagic
symptoms in infected humans, leads to spontaneous miscarriage in pregnant livestock
and causes high rates of mortality in young animals (13, 101). Currently there are no
therapeutics or FDA approved vaccines to combat bunyaviral infection. This is in part
due to a lack of understanding of the molecular interactions occurring between
bunyaviruses and host cells. We set out to identify host factors that restrict RVFV
infection in insects using Drosophila as our model insect due to the ease of genetic
manipulation both in vitro and in vivo. RNAi in Drosophila cells is robust, and conserved
immune biology with humans has been demonstrated (e.g., Toll)(72), suggesting that we
can use Drosophila to probe both insect and human antiviral factors (26, 58, 88, 107,
108, 112). Furthermore, Drosophila has been used as a model to study arboviral
infection, including RVFV (45, 88, 93, 107, 108, 112).
Using genome-wide RNAi screening in Drosophila cells, we identified 131 genes
that impact RVFV (strain MP12) infection, including Dcp2, the P body resident mRNA
decapping enzyme. Dcp2 restricts RVFV in Drosophila and mosquito cells and also in
adult flies. This restriction is likely general to bunyaviruses, since the distantly related
bunyavirus La Crosse virus is also restricted by Dcp2. Mechanistically, we found that the
viral nucleocapsid (N) is localized to P bodies, and RVFV competes with the RNA
degradation machinery for target mRNAs. Increasing the pool of mRNAs targeted for
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degradation via the depletion of Dcp2 or cell cycle arrest in late S/early G2 led to
increased RVFV replication, while decreasing targets via ectopic expression of Dcp2
restricted infection. Therefore, our data point to a model in which the pool of Dcp2accessible mRNAs is dynamically regulated and presents a bottleneck for RVFV
replication.

2. Results

Genome-wide screening implicates the mRNA decapping machinery as a
restriction factor for RVFV
In order to identify host factors that restrict RVFV, we performed a high-content
genome-wide RNAi screen in Drosophila cells. Briefly, 384-well plates were arrayed with
dsRNAs targeting approximately 13,000 genes in the Drosophila genome (Ambion);
Drosophila cells were seeded and knockdown was allowed to proceed for three days.
Cells were then infected with the MP12 strain of RVFV (MOI= 0.25) (23), which differs by
only 11 amino acids from the wild type strain ZH548, making it likely that cellular factors
that impact MP12 replication will also impact wild type strains (134). 30 hours post
infection (hpi), cells were stained for total nuclei and RVFV nucleocapsid (N). Automated
microscopy, followed by automated image analysis was used to calculate the average
percent infection per well (RVFV N positive cells/total cells) from four sites per well, and
the screen was performed in duplicate. Genes with a Robust Z-score ≥1.3 or ≤-1.3 in
duplicate (p<0.05) that were non-toxic (Robust Z-score ≥-2 in duplicate) were considered
hits (Figure 3.1A). 179 genes were identified, amongst which 56 were part of multisubunit complexes (e.g., ribosome, proteasome). Therefore, we chose only 1 or 2 genes
per complex to verify as a representative, leaving 143 genes to validate. We generated
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independent dsRNAs targeting unique regions of 143 genes from the initial set and
validated 85 genes. Including the genes identified in the primary screen that were
validated by another member of their complex, this comes to 131 genes. 124 genes
restricted infection while 7 promoted infection (Figure 3.1B, 3.2, Table 6.1). In addition,
Gene Ontology (GO) enrichment analysis indicated that these candidates were
significantly enriched for genes involved in DNA replication, the cell cycle and mRNA
metabolic processes (Figure 3.1C). Importantly, our gene list was also enriched for
genes conserved with humans and mosquitoes; 124 were conserved with mosquitoes
and humans, 4 were conserved in mosquitoes, while only 3 did not have identified
orthologs in these groups. This suggests that the factors and pathways identified may
have conserved interactions with RVFV replication across multiple relevant hosts.
Additionally, we validated three genes that reside in P bodies (115): the
canonical mRNA decapping enzyme Dcp2, LSM7 (part of the heptameric LSM1-7
complex that participates in decapping activation) (95) and the Drosophila homolog of
human DDX6/Rck/p54 (Me31B), which has been characterized as an activator of
decapping in yeast (35, 46), although its mechanism is unclear (94, 122, 142) (Figure
3.1B, 3.2, 3.3A-C, 3.4, Table 6.1). P body components participate in multiple mRNA
degradation pathways, including silencing and decapping (40), and P body morphology
can be altered by the loss of specific P body components. Loss of Dcp2 leads to
increased P body size, while the loss of DDX6 leads to the dispersal of P bodies in
Drosophila (data not shown, and (42)). Furthermore, visible P bodies are not necessarily
required for functional activity of P body resident proteins, including RNA silencing,
nonsense mediated decay and mRNA decay (42). Therefore, we set out to elucidate
whether P bodies themselves or particular functions within P bodies, such as decapping,
were specifically involved in RVFV restriction. We screened 7 other canonical P body
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resident proteins, including HPat (Patr-1), GW182 (gw), Dcp1 (a binding partner for
Dcp2), EDC4 (Ge-1), staufen (stau), LSM14A (tral, not part of the LSM1-7 complex) and
EDC3, and found that none of them impacted RVFV replication greater than 2-fold,
although loss of LSM14A or EDC3 led to modest, but significantly increased levels of
RVFV infection (Figure 3.3C). Interestingly, LSM14A and EDC3 are mRNA decapping
activators in yeast (95) and are required for DDX6 recruitment to P bodies in Drosophila
(125), suggesting their effects may be through this mechanism. Our data suggest that
while RVFV replication is restricted by mRNA decapping (Dcp2 and four decapping
activators), P body integrity is not essential for this restriction or for RVFV replication.

Dcp2 restricts the bunyavirus RVFV but not other families of RNA viruses
In order to determine the specificity of this restriction, we tested whether Dcp2
impacts the replication of RNA viruses from three disparate families: Drosophila C virus
(DCV), Sindbis virus (SINV) and Vesicular stomatitis virus (VSV). DCV is a positive
sense RNA picorna-like virus and natural pathogen of Drosophila (32, 67). DCV does not
use a 5’ cap for translation but rather couples a protein to the 5’ end for protection and
uses internal ribosome entry sites for translation (110). SINV is a human arbovirus that is
a positive sense RNA alphavirus, and VSV is an arbovirus that is a negative sense
single stranded RNA rhabdovirus; both of these viruses encode their own 5’ capping
machinery (2, 73). We found that Dcp2 specifically restricts RVFV, since depletion of
Dcp2 has no impact on the level of infection by DCV, SINV or VSV (Figure 3.3B). Since
the only known role for Dcp2 is in decapping, and it selectively restricted RVFV, we
hypothesized that decapping per se specifically limits RVFV replication through this
biological function.
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RVFV N associates with P bodies
Since we identified P body resident proteins as antiviral against RVFV, we tested
whether the viral replication machinery and P bodies interact during RVFV infection.
Previous studies of the distantly related bunyavirus Sin Nombre virus found that the
nucleocapsid protein (N), necessary for cap-snatching, forms visible punctae in
mammalian cells that colocalize with the P body resident protein DCP1a (83). We
generated cells expressing Dcp1-GFP, which labels P bodies (42), and infected them
with RVFV for 30 hours. Analysis of these cells demonstrated that N punctae partially
overlapped with P body punctae (Figure 3.5A). More than half of the infected cells
presented with at least one colocalization (Figure 3.5B). Furthermore, the majority of
these events presented with partial overlap rather than complete colocalization (only 3
colocalizations were found to be coincident), resembling previous reports showing that P
bodies may contain distinct compartments (111, 141). Additionally, colocalization studies
examining P bodies and the Ty3 retrotransposon in yeast have shown similar patterns of
partial overlap (9). Since Dcp2, but not Dcp1, is antiviral (Figure 3.3C), we next
examined whether Dcp2 colocalized with RVFV N. We generated cells expressing mycDcp2 (65) and infected them with RVFV for 30 hours. We found that coincident
colocalization occurred in ~90% of infected cells (Figure 3.3D, E), while only a small
subset of cells showed instances of partial overlap between RVFV N and Dcp2 punctae
(~2%). Interestingly, when we co-expressed Dcp1-GFP and myc-Dcp2, we saw a
spectrum of overlap where the large majority of punctae had substantial overlap of Dcp1
and Dcp2, while others showed partial overlap or no overlap (Figure 3.5C). This
suggests complexity to these compartments. Taken together, our data suggest that
RVFV, and perhaps bunyaviruses in general, interacts with P bodies or P body resident
proteins.
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Dcp2 restricts bunyavirus infection in adult flies
We set out to determine the role of Dcp2 in antiviral defense against RVFV at the
organismal level in adult flies (45). Arboviral infection of the insect host is controlled by
the innate immune system. If compromised, an otherwise non-lethal infection can
become pathogenic and potentially fatal (108, 132, 136). Since Dcp2 is an essential
gene (79, 103), we used in vivo RNAi technology to deplete Dcp2 post-developmentally
in adult flies to determine the impact of the decapping machinery on RVFV replication.
Briefly, transgenic flies bearing a UAS element driving the expression of an inverted
repeat (IR) against Dcp2 were crossed to flies expressing the Gal4 protein under the
control of a heat shock inducible promoter. Adult flies were subjected to heat shock,
driving expression of the snap-back transgene and mRNA depletion, which had no
impact on survival (Figure 3.5A, B). As expected, control flies infected with RVFV
presented with little mortality; however, Dcp2-depleted flies succumbed to RVFV
infection (Figure 3.6A). This increase in mortality was accompanied by increased levels
of viral replication as measured by northern blot at 6 days post infection (Figure 3.6B, C).
We also examined viral RNA levels at 20 days post infection, when flies are dying from
infection, and found that while we see less of an increase in Dcp2 depleted flies
compared to day 6, increased replication continues late into infection (Figure 3.7C, D).
We hypothesize that the differences we see are greater at day 6 due to highly infected
flies in the population succumbing to infection by day 20 post infection. Additionally, we
tested whether decapping restricted another distantly related bunyavirus, La Crosse
virus (LACV), an orthobunyavirus transmitted by mosquitoes to humans (53, 57). Control
flies challenged with LACV presented with little mortality, while Dcp2-depleted flies
succumbed to LACV infection (Figure 3.6D). Additionally, we found increased viral RNA
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levels in flies infected with LACV as measured by quantitative RT-PCR 6 days post
infection (Figure 3.7E). Thus, Dcp2 restricts bunyaviruses both in cell culture and in vivo
in adult flies.

Decapping restricts RVFV in Aedes aegypti mosquito cells
RVFV is unusual among arboviruses in that it has been isolated in nature from a
large number of mosquito species, and numerous mosquitoes can experimentally
transmit this virus, including Aedes aegypti, the major vector for Dengue virus (128).
Since there are no cell lines available for many of the more common vector mosquitoes
that transmit RVFV, and their genomes have not been sequenced, we took advantage of
the fact that Aedes aegypti is a sequenced vector mosquito. Aag-2 cells, derived from
these mosquitoes, are permissive to RVFV and amenable to robust RNAi (Figure 3.6E)
(22, 89). There are two annotated Dcp2 orthologs in the Aedes aegypti genome
(AAEL015607 and AAEL000783) with 99% amino acid sequence identity, allowing us to
design a single dsRNA targeting a conserved region of both Dcp2 genes to deplete both
simultaneously. Aag-2 cells were subject to RNAi using the same method as with
Drosophila cells. Three days post RNAi cells were challenged with RVFV (MOI of 0.06)
for 24 hours, fixed and stained for total nuclei (blue) and RVFV N protein (green).
Automated microscopy and automated image analysis revealed a significant increase in
the percentage of RVFV infected Dcp2-depleted mosquito cells (Figure 3.6E, F),
suggesting that decapping is a conserved mechanism of bunyaviral restriction among
insects.

Dcp2 does not restrict RVFV by directly decapping viral mRNAs
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One major difference between the replication strategies of segmented negative
sense viruses (RVFV, LACV) and non-segmented negative sense viruses (VSV) is the
mechanism by which they cap their viral mRNAs. While VSV encodes its own 5’ capping
machinery (VSV L) (73), RVFV does not. Rather, all segmented negative sense RNA
viruses (bunyaviruses, arenaviruses and orthomyxoviruses) “cap-snatch” the 5’ ends of
host mRNAs, simultaneously defending the 5’ end of their mRNAs from exonucleases
and facilitating translation. Bunyavirus encoded nucleocapsid (N) protein specifically
binds the 5’ caps of host mRNAs (85). The viral RNA-dependent RNA polymerase (L),
which has endonucleolytic activity (100, 106), then cleaves host mRNAs 10-18
nucleotides downstream of the 5’ cap and uses this primer as a template for viral mRNA
transcription (17, 100, 116). Thus, all viral mRNAs from this family (RVFV encodes 4
mRNAs (Figure 3.8)) begin with a short sequence of nucleotides of non-viral origin.
We reasoned that if Dcp2 restricts RVFV replication at the step of cap-snatching,
there are 3 likely mechanisms: 1) Dcp2 may be restricting the pool of available host
mRNAs through normal metabolic turnover (indirect mechanism); 2) following cleavage
by the viral L protein, short host-derived primers may be decapped prior to viral RNA
transcriptional elongation; 3) Dcp2 may be directly decapping host mRNA-viral mRNA
conjugates following or concomitant to viral transcription (direct mechanism). The
second mechanism is highly unlikely; following cap-binding and cleavage the 5’ cap is
bound by viral proteins and thus likely occluded from Dcp2 recognition (84), and in
yeast, Dcp2 has been shown to be largely inactive on mRNAs <30bp (120).
In order to clarify which of the other mechanisms restricts RVFV, we took two
approaches: we first assayed the cap status of viral mRNAs in the presence or absence
of Dcp2, and second, we examined the decay rate of viral mRNA species in the
presence or absence of Dcp2. First, we developed an assay to distinguish capped
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mRNAs from those that have been decapped by Dcp2, which leaves a 5’
monophosphate on mRNAs following cap cleavage (90). Terminator Exonuclease
degrades 5’-monophosphate bearing RNAs, including those which are the product of
Dcp2-mediated decapping. Cellular 28S rRNA, which natively has a 5’ monophosphate,
was completely digested by this enzyme (Figure 3.9A, B), while the capped mRNA
dRPS6 remains largely intact (95% protected, Figure 3.9A, C, D). We also analyzed the
level of background digestion that occurs in this assay by radiolabeling the cap of GFP
mRNA transcribed in vitro and then subjecting these capped mRNAs to digestion in the
presence or absence of cellular mRNA, as this is the context of our experimental
samples. We found that without cellular RNA, ~18 percent of the GFP signal was lost in
digested samples compared to mock controls. Interestingly, this level of digestion was
reduced to ~12 percent with the addition of cellular RNA, presumably due to the
abundance of rRNA competing for digestion (Figure 3.10A).
If Dcp2 were directly decapping viral mRNAs post cap-snatching, loss of Dcp2
would increase the proportion of undigested viral mRNA (capped) present in the viral
RNA pool. Conversely, if Dcp2 were decapping the mRNA substrates available for RVFV
to snatch from, there would be no change in the relative proportion of mRNA that was
digested, even though there would be an increase in overall viral mRNA levels.
Since the N and NSs mRNAs are significantly different in size from their genomic
segment, this allows us to distinguish them from the S genomic RNA. In contrast, the
other viral mRNAs are not sufficiently different in size from the genomic RNA to
distinguish by northern blot (Figure 3.8). Thus, we chose to examine the N transcript
since it is essential; NSs is dispensable for replication in cell culture (14). We found that
~75% of the viral N mRNA was protected from digestion in control cells, presumably by a
5’ cap (Figure 3.9F); accounting for background levels of digestion, this suggests that
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anywhere from 13-25% of the viral mRNA is uncapped natively. Moreover, we observed
that Dcp2 knockdown leads to an overall increase in viral N mRNA levels (Figure 3.9A,
E); however, Dcp2 knockdown did not significantly alter the proportion of protected N
mRNA (Figure 3.9A, F). This suggests that Dcp2 does not directly decap viral mRNAs.
Furthermore, we found that Dcp2 does not seem to regulate the steady-state levels of
the housekeeping mRNA dRPS6, as there is no change in dRPS6 mRNA in the
presence or absence of Dcp2, with or without digestion (Figure 3.9A, C, D). These
findings suggest that Dcp2 restricts the RNA substrates available for RVFV-mediated
cap-snatching and does not globally affect the cap status of mRNAs within the cell. This
is consistent with the finding that Dcp2 does not globally regulate mRNA turnover, but
impacts the stability of only small subsets of mRNAs from yeast to humans (75, 77, 146).
Furthermore, depletion of the P body resident 5’ to 3’ exonuclease Xrn1, does not impact
viral infection levels, N transcript levels, or digestion assay results, suggesting that viral
mRNAs themselves are not under considerable pressure from the 5’ to 3’ degradation
pathway (Figure 3.10 B, C, D).
Since there was a degree of background digestion occurring with the
exonuclease assay, we set out to directly determine whether Dcp2 impacted viral mRNA
stability. Unlike cellular mRNAs, whose decay can be measured by treatment with
Actinomycin D and subsequent monitoring for loss of mRNA, viral RNA dependent RNA
polymerases are refractory to Actinomycin D preventing the use of this approach.
However, a unique feature of bunyaviruses is that transcription of mRNAs is coupled to
translation (7); therefore, treatment with cycloheximide (CHX), which inhibits
translational elongation, prevents viral mRNA transcription, allowing us to examine the
rate of viral mRNA decay.
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For these studies, we infected dsRNA treated Drosophila cells with RVFV for 28
hours, and then treated cells with CHX. We collected total RNA every 30 minutes and
examined viral mRNA levels via northern blot (Figure 3.9G). RVFV N mRNA has a halflife of ~30 minutes (Figure 3.9H). Furthermore, RVFV N mRNA decayed at the same
rate in Dcp2-depleted and control cells (luciferase) (Figure 3.9H), suggesting that Dcp2
is not affecting viral mRNA stability. Furthermore, we observed no changes in viral
genome levels over time with CHX treatment in the presence or absence of Dcp2,
indicating that short-term disruption of translation does not globally impact the stability of
other RNA species (Figure 3.9I). Altogether, these data suggest that Dcp2 is not directly
decapping viral mRNAs, but rather decaps specific pools of mRNA that are the
preferential targets of RVFV cap-snatching.

RVFV selectively snatches cell cycle related mRNAs
As our results suggest that Dcp2 and RVFV compete for the same pool of mRNA
targets, we set out to determine which mRNAs were being snatched. This may also
reveal the particular mRNAs that are regulated by Dcp2-dependent decapping. Thus, we
performed 5’ RNA ligase mediated (RLM)-RACE and sequenced the 5’ ends of viral N
mRNA transcripts from RVFV infected Drosophila cells. Of the 40 sequenced reads, we
were able to align 33 to the 5’ end of endogenous RNAs (Figure 3.11A, 3.8). Of these
33, we found 4 instances in which we found the same gene being snatched in
independent experiments, leaving 29 independent genes. There were no obvious
consensus sequence motifs within this gene set, suggesting that if there are structural or
sequence specific motifs targeted by Dcp2, they are not contained within the first 15
nucleotides. We found that while 9 of the 29 genes had no annotated GO terms, half of
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the remaining 20 genes (10) had terms associated with the cell cycle and mitosis (Figure
3.11A, 3.12).
To determine whether the stability of these target mRNAs is impacted by Dcp2,
we performed RNAi in Drosophila cells and assayed host mRNA levels by quantitative
RT-PCR. We found that indeed, mRNA levels for three genes tested (CG8878, CG7580
and Jupiter) were increased upon Dcp2 depletion (Figure 3.11B). To determine if these
genes were used as a target for RVFV snatching, we used a forward primer containing
the first 11bp of either CG8878 or Jupiter, in addition to another gene identified, Histone
3 (His3), a replication-dependent histone, and a reverse primer in the N transcript. Using
this assay, we found that the viral Host-N fusion mRNAs were increased upon Dcp2
knockdown as compared to control (Figure 3.11D). These data suggest that Dcp2
affects RVFV replication primarily by restricting the substrate mRNAs available for capsnatching, and that cell cycle mRNAs are targeted both by decapping and capsnatching.

P body morphology is regulated by the cell cycle
Interestingly, previous studies in human HeLa cells suggested the rapid turnover
of replicating histone mRNAs (such as His3) at the end of S phase is dependent on
Dcp2 (92, 121). This observation, along with our identification of a large number of cell
cycle related mRNAs as targets of RVFV-dependent cap-snatching, suggests that cell
cycle related mRNAs are degraded by Dcp2 in Drosophila. Emerging data also suggest
that P bodies are regulated by a number of different biological inputs, including the cell
cycle. P body size and number increase as mammalian cells exit S phase and enter G2
(145). This may be due to the influx of mRNAs encoding DNA replication machinery and
histones that need to be degraded, and this accumulation may result in increased
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granule assembly leading to increased P body size. We examined whether P body size
or number was influenced by the cell cycle in Drosophila. We used RNAi against cyclins
to arrest the cells in G1 (CycD knockdown) or late S/G2 (CycA knockdown) (11). As
expected, we observed an increase in nuclei size upon S/G2 arrest (Figure 3.11E). This
was concomitant with a significant increase in P body area and number (Figure 3.11F,
G), suggesting that cell cycle dependent regulation of P bodies is deeply conserved, and
that P body size during the cell cycle may serve as a marker for the load of mRNAs
destined for degradation.

Cell cycle arrest in late S/early G2 enhances RVFV replication
Since P body size is regulated by the cell cycle with the apex at late S/early G2,
which is likely due to increased targeting of RNAs for degradation, and mRNA target
levels are seemingly a bottleneck for RVFV replication, we hypothesized that RVFV may
replicate most efficiently when P bodies are at their largest and P body mRNAs are in
high abundance. Indeed, analysis of our validated RNAi screen gene set revealed 39
genes that had the GO term “cell cycle” and were antiviral (Figure 3.1C, 3.2).
Furthermore, the entire DNA replication factor A complex (RPA2, RpA-70 and
CG15220), whose depletion results in S phase arrest, was also antiviral in our screen
(Figure 3.2, Table 6.1). Moreover, we found that 28 genes impacted the cell cycle
arresting at S/G2, as measured by increased nuclear area upon depletion (Figure 3.2,
Table 6.1), of which 26 genes were antiviral and 15 genes did not have an annotated
GO term associated or literature reference to the cell cycle, suggesting that they may
have a previously unknown role in the cell cycle. To validate this, we performed RNAi
against a panel of genes that arrest the cell cycle at specific stages. Treatment of cells
with dsRNA to arrest in S/G2 (CycA, cdc2, RnRs) led to increased levels of infection,
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while arrest in G1 (CycD, cdc2c, CycE) had no impact (Figure 3.13A, B), consistent with
the fact that in log phase, >80 percent of Drosophila cells are in G1 (18). Furthermore,
we observed increases in RVFV mRNA upon loss of CycA, but not CycD, as measured
by northern blot (Figure 3.13C, 3.14A), along with increased His3-N mRNA accumulation
(Figure 3.13D). To determine whether this was specific for RVFV infection, we
challenged arrested cells with VSV. We found that VSV replication was unaffected by
S/G2 arrest, while G1 arrest by cdc2 modestly promoted infection (Figure 3.13B).
Altogether, this data suggests that cell cycle arrest in late S/early G2 is advantageous for
RVFV replication, and this enhancement is specific to bunyaviruses.

Diverse bunyaviruses are restricted by similar mechanisms in cells
Our finding that Dcp2 restricts LACV in adult flies prompted us to test this in cell
culture. Depletion of Dcp2 in Drosophila cells led to increased levels of LACV replication
as measured by viral RNA levels; similar results were seen with DDX6 depletion (Figure
3.13E, 3.14B). Next, we tested if LACV, like RVFV, also replicated more efficiently in late
S/early G2, a time when Dcp2-targeted mRNAs should be abundant. Indeed, we found
that S/G2 arrest led to increased LACV RNA replication (Figure 3.13E, 3.14B). These
data suggest that cap-snatching is a bottleneck in the bunyaviral life cycle and that
modulation of target mRNA levels impacts the replication of diverse bunyaviruses.

Dcp2 is limiting: ectopic expression restricts RVFV replication
Since loss of Dcp2 leads to increased replication, we hypothesized that enforced
expression of Dcp2 may restrict RVFV replication by decapping, and thereby limiting, the
pool of available mRNAs. First, we confirmed that RNAi against Dcp2 substantially
depleted myc-Dcp2 in our Dcp2 expressing cells by immunoblot (Figure 3.15A). Next,
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wild type or Dcp2-expressing cells were infected with RVFV, and immunoblot analysis of
RVFV glycoprotein (RVFV Gn) revealed that Dcp2 knockdown increases RVFV infection
(Figure 3.15A), consistent with our findings measured by microscopy (Figure 3.3A) or
northern blot (Figure 3.9E). Additionally, we found that ectopic Dcp2 expression
significantly restricted RVFV infection as measured by both immunoblot (Figure 3.15A)
and by microscopy (Figure 3.15B). Furthermore, Dcp2 knockdown restored infection in
ectopically Dcp2-expressing cells to wild-type levels (compare to luciferase treated
infected cells (Figure 3.15A, B). These treatments had no effect on VSV infection (Figure
3.15C), demonstrating specificity. Therefore, Dcp2 levels define a set point for RVFV
infection.

3. Discussion
Our genome-wide RNAi screen identified and validated a large number of genes
that restrict RVFV replication. Amongst this gene set was the canonical mRNA
decapping enzyme Dcp2 and two decapping activators. The interactions between mRNA
decay and viral infection are an area of burgeoning study (38, 49, 86); however, there is
little known about the intersection of the RNA degradation machinery and bunyaviral
infection, and so we explored this biology. Future studies will reveal the mechanistic
roles the other validated factors play in viral infection. We focused on Dcp2, which
specifically restricts the replication of two diverse bunyaviruses (RVFV and LACV) but
not other RNA viruses, in insects both in vitro and in vivo. Bunyaviruses, unlike the other
RNA viruses tested, use cap-snatching to generate the 5’ end of viral mRNAs. This is in
part mediated by the bunyaviral N protein, which binds to 5’ capped mRNAs (85). This
led us to postulate that RVFV cap-snatching competes with decapping, and suggests a
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model in which the availability of mRNA substrates is rate limiting for RVFV infection.
Thus, modulation of these targets can create or eliminate a bottleneck in viral replication.
Indeed, we find that Dcp2 does not directly decap viral transcripts after snatching
and transcription have occurred, as knockdown does not impact the cap status of viral
mRNAs (Figure 3.9F) or their stability (Figure 3.9G, H), and furthermore, that Xrn1
knockdown does not increase viral mRNA stability (Figure 3.10B, C, D). Rather, mRNA
decapping during normal RNA turnover keeps the pool of available mRNA targets from
which bunyaviruses can snatch at a low level. Thus, loss of the decapping enzyme Dcp2
leads to increased bunyaviral replication, and ectopic expression of Dcp2 restricts
infection. Furthermore, we found that many mRNA targets that are snatched and
incorporated into viral transcripts are cell cycle related. Indeed, mRNA levels in P bodies
are cyclically altered in phase with the cell cycle. As cells transit into late S/early G2, P
bodies enlarge to accommodate mRNA degradation of mRNAs required for DNA
replication, and these cells support higher levels of bunyaviral replication. Our genomewide RNAi screen identified a large number of cell cycle genes, including all three
subunits of the DNA replication factor A complex, that arrest the cell cycle at this time as
antiviral. Interestingly, however, we find that P body dispersion through knockdown of
components known to be required for P body integrity does not affect RVFV replication;
this is consistent with data showing that microscopically visible P bodies are not required
per se for P body associated functions, such as miRNA silencing and NMD decay.
Indeed, our data strengthen previous findings that P body morphology may be a marker
for the accumulation of mRNAs destined for degradation within the cell.
We found that by modulating the pool of host mRNAs targeted for decapping,
either through changes in the expression level of Dcp2, or by arresting cells in late
S/early G2 phase, bunyavirus replication is affected in insects. Interestingly, mRNAs
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carrying nonsense mediated decay signals were incorporated at an increased rate into
Sin Nombre transcripts in human cells, and Sin Nombre N localizes with P bodies (83).
This suggests potential conservation of decapping as antiviral against bunyaviruses in
mammals. In further support of this, Dcp2 is inducible by Type I interferons (75, 109).
While Drosophila only encode one characterized decapping enzyme, a second
decapping enzyme (NUDT16) has been recently characterized in both mice and humans
(117), and an additional six nudix domain containing proteins in mice and one in yeast
have been shown to have various degrees of decapping activity (119). Drosophila
encodes no NUDT16 ortholog, however it does encode for 14 other nudix domain
containing proteins, none of which were identified as antiviral in our genome-wide
screen. Recent studies have identified a novel decapper in bacteria, which do not cap
their RNA, suggesting that decapping activity is ancient and preceded mRNA capping in
evolution (119). This may further support a role for decapping in antiviral defense.
Interestingly, comparisons have revealed that DCP2 and NUDT16 have both redundant
and specific targets (76), suggesting that in eukaryotes, decapping may be far more
complex than first thought.
One interesting question raised by these observations is why bunyaviruses
transcribe their viral mRNA in an area rife with mRNA degradation machinery. This is
particularly perplexing when considering the fact that viral RNA transcription is
dependent on translation, and P bodies are ribosome-free. We have four hypotheses
that might explain why bunyaviruses use mRNAs destined for degradation as the target
for cap-snatching. First, these targets are largely present in a spatially concentrated area
and destined for degradation. Thus, snatching caps from these mRNAs should not
negatively impact cell viability. Second, cytoplasmically replicating RNA viruses must
compartmentalize their replication steps in order to enhance efficiency; segregating RNA
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transcription to these areas (P bodies) may prevent competition between cap-snatching,
genome replication and viral RNA packaging into virions. Third, microscopy studies
indicate that P bodies, and perhaps the RNA degradation machinery in general, are
surrounded by ribosomes (36, 141). Furthermore, recent studies in Drosophila have
shown that during oogenesis and early egg activation, translation of mRNAs necessary
for proper axis formation depends upon RNA localization within sub-compartments of P
body like RNPs (141). RNAs located deep within the P body core are associated with
decapping activators and are translationally repressed, while those located towards the
edge of the P body are able to interact with ribosomes associated with the periphery of
the P body and can initiate translation. This pool of readily available ribosomes may be
optimal for initiation of translation of viral mRNAs, since bunyaviral mRNA transcriptional
elongation requires translation to be occurring concomitantly (7). Thus, it is possible that
these ribosomes serve this function. Finally, we speculate that the 5’ end of the host
mRNA molecule, once cleaved, may represent an abnormal or ’foreign’ RNA structure to
the host cell (5’ monophosphate on an RNA with a 3’ polyA tail). While cellular RNA
molecules exist with 5’ monophosphates, such as rRNA, these RNAs are heavily
associated with proteins, which may occlude recognition of their 5’ end structure, and
are not polyadenylated. Snatching in these localized environments may assure that
mRNAs that are targeted for snatching can be rapidly degraded by the P body resident
processive exonuclease, Xrn1. Indeed, there may be parallels between bunyaviral
snatching of Dcp2 targeted pools in the cytoplasm and nuclear pre-mRNAs by
orthomyxoviruses. Many pre-mRNAs are aberrantly synthesized, and therefore the
nucleus has surveillance machinery, which includes an Xrn1 homolog Rat1 that targets
uncapped mRNAs for degradation. Therefore, in both cases the uncapped host mRNA is
under close surveillance and thus has a very short half-life.
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Altogether, we have explored the host factor dependencies of RVFV, leading to
the finding that two diverse bunyaviruses are restricted by mRNA decapping.
Furthermore, these studies have revealed new aspects of RNA decay and the regulation
of these compartments; our results indicate that alteration of P body morphology during
cell cycle progression is a deeply conserved process from insects to mammals (145).
We also provide evidence that in Drosophila, Dcp2 decaps mRNAs involved in cell cycle
progression and DNA replication, in addition to previously established roles in regulating
histone mRNA levels in human cells (92). This suggests that decapping in Drosophila
more generally targets mRNAs undergoing rapid turnover. RNA profiling studies in
murine cells depleted of Dcp2 or NUDT16 suggest that in higher organisms the
decapping of mRNAs is specialized (75). Thus, selective activation of decapping may
potentially be a viable therapeutic approach to degrade RVFV accessible mRNAs.
Indeed, Dcp2 is potentially regulated: in yeast, phosphorylation of Dcp2 by Ste20 is
necessary for Dcp2 recruitment to P bodies (146), and vertebrate Dcp2 has a number of
conserved uncharacterized phosphorylation sites (62). Further studies will reveal
whether decapping of specific cargo can be selectively regulated in insects and
mammals.

43

Figure 3.1. Genome-wide RNAi screen for host factors that impact RVFV in Drosophila.
(A) Genome-wide RNAi screen pipeline. Cells were plated onto 384 well plates pre-plated with
dsRNAs targeting the Drosophila genome. Three days later cells were infected with RVFV MP12
(MOI=0.25) for 30 hours and processed for immunofluorescence (RVFV N, green; nuclei, blue).
Automated microscopy followed by image analysis was used to calculate Robust Z-scores, which
are shown for each replicate of the screen. (B) Primary candidates were validated using
independent dsRNAs; for complexes with multiple candidates represented in the primary pool, a
selection of genes were validated as representative of the complex. Robust Z-scores from 143
genes shown with validated genes in blue, genes that did not validate in grey. Dcp2, DDX6 and
LSM7 are shown in red, green and orange, respectively. (C) GO term enrichment for validated
genes.
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Figure 3.2. Validated screen hits assigned to cellular functions based on informatics
analysis. Human gene names are shown for all orthologs. Genes in red are pro-viral, green are
antiviral and black are members of large complexes not directly tested in secondary validation.
Rab5C and SUPT5H were previously validated and are bolded (45, 143). Underlined genes have
the GO term “cell cycle,” and an asterisk indicates S phase associated genes in the literature.

45

Figure 3.3. Decapping restricts RVFV replication in Drosophila cells.
(A) Drosophila cells were treated with the indicated dsRNA for 3 days, then infected with RVFV
(MOI 0.01) and processed for immunofluorescence (RVFV N protein, green; nuclei, blue). (B)
Cells were treated as in A and infected with the indicated virus. dsRNA targeting each virus was
used as a positive control (Virus). Quantification of mean fold change in the percentage of cells
infected with the indicated virus is shown. Blue – Drosophila C Virus (DCV), purple – Sindbis
virus (SIN), red – Vesicular Stomatitis virus (VSV), green – RVFV (MP12 strain). Mean±SD of ≥3
independent experiments; **p<0.01. (C) Cells treated as in A with P body component dsRNAs
were quantified for the mean fold change in the percentage of RVFV infected cells. Decapping
activators are indicated, and genes significantly affecting RVFV replication are highlighted in blue.
Mean±SD of ≥3 independent experiments; *p<0.05. (D) Representative deconvolved plane of a
Drosophila cell expressing myc-Dcp2 (green) and infected with RVFV for 30 hours (RVFV N red,
nuclei blue). (E) Quantification of RVFV N and myc-Dcp2 punctae colocalization events per cell
(>150 cells from 3 independent experiments). The majority of infected cells (~90%) have at least
one colocalization between Dcp2 and RVFV N.
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Figure 3.4. Knockdown efficiency of dsRNAs. Quantitative RT-PCR analysis of Dcp2 (A) and
DDX6 (B) in cells treated with the indicated dsRNA normalized to RP49 levels and shown relative
to non-targeting control (luciferase).
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Figure 3.5. Colocalization of Dcp1 with RVFV and Dcp2. (A) Representative deconvolved
plane of a Drosophila cell expressing Dcp1-GFP (green) and infected with RVFV for 30 hours
(RVFV N red, total nuclei blue). (B) Quantification of RVFV N and Dcp1-GFP punctae
colocalization events per cell (>300 cells from 3 independent experiments). The majority of
infected cells (54.3%) have at least one colocalization between Dcp1 and RVFV N, although they
are not coincident. (C) Representative deconvolved plane of a Drosophila cell expressing mycDcp2 (red) and Dcp1-GFP (green). Total nuclei stained in blue. The majority of punctae are both
Dcp2 and Dcp1 positive with partial overlap shown as closed arrows. However there are some
punctae that are only Dcp1 or Dcp2 positive shown as dotted arrows.
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Figure 3.6. Dcp2 restricts bunyaviruses in flies and mosquitoes.
(A) Adult flies carrying heat shock inducible Gal4 were crossed to flies that inducibly express
dsRNA against Dcp2 (hs-Gal4>UAS-Dcp2 IR, red) or controls (hs-Gal4>+, blue) were challenged
with RVFV, and percent survival is graphed as a function of days post infection (dpi). A
representative of at least three experiments is shown; p<0.001 log rank test. (B) Northern blot
analysis of RVFV infected control flies and Dcp2-deficient flies probed for RVFV N mRNA or
dRPS6 (cellular loading control) 6 days post infection. (C) Quantification of 3 experiments as
shown in B. Mean±SD; *p<0.05. (D) Flies as described in A were challenged with La Crosse
virus (LACV). Percent survival is graphed as a function of time. A representative of at least three
experiments is shown; p<0.001 log rank test. (E) Representative immunofluorescence of Aedes
aegypti Aag-2 cells treated with the indicated dsRNA and subsequently infected with RVFV. (F)
Quantification of mean fold change in percent infection with mean±SD shown; **p<0.01.
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Figure 3.7. Supplemental information for whole animal experiments. (A) Survival of
uninfected flies of the indicated genotypes. (B) Quantitative RT-PCR analysis of Dcp2 in adult
heat shocked flies normalized to RP49 levels and shown relative to control flies. (C) Northern blot
analysis of RVFV infected control flies and Dcp2-deficient flies probed for RVFV N mRNA or
dRPS6 (cellular loading control) 20 days post infection. (D) Quantification of 3 experiments as
shown in C. Mean±SD; *p<0.05. (E) Quantitative RT-PCR analysis of LACV N/S RNA levels
normalized to RP49 in infected flies of the indicated genotypes day 6 post infection. Mean±SD for
≥3 independent experiments; *p<0.05.
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Figure 3.8. Schematic of RVFV genomic RNA, mRNA and protein coding strategy.
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Figure 3.9. Dcp2 does not directly degrade viral mRNA.
(A) Drosophila cells treated with the indicated dsRNA and infected with RVFV; total RNA was
either mock treated or digested with Terminator Exonuclease as indicated. Northern blots were
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Figure 3.9 (cont.): probed for RVFV N mRNA (capped transcript), 28S rRNA (5’ monophosphate bearing control transcript) or the cellular capped dRPS6 mRNA. (B) Quantification of
28S rRNA as shown in A, normalized to luciferase mock treated. Mean±SD for ≥3 independent
experiments; *p<0.05. (C) Quantification of RVFV N mRNA in mock digest samples normalized to
luciferase control. Mean±SD for ≥3 independent experiments; *p<0.05. (D) Ratio of digested
RVFV N mRNA divided by the mock treated sample, yielding the ratio of mRNA that is refractory
to digestion. Mean±SD for ≥3 independent experiments; n.s. not significant. (E) Quantification of
dRPS6 transcript in mock digest samples normalized to luciferase control. Mean±SD for ≥3
independent experiments; n.s. not significant. (F) Ratio of digested dRPS6 mRNA transcript
divided by the mock treated sample, yielding the ratio of mRNA that is refractory to digestion.
Mean±SD for ≥3 independent experiments; n.s. not significant. (G) Drosophila cells were treated
with the indicated dsRNA and infected with RVFV. 28 hours post infection, cells were treated with
cycloheximide (CHX), and total RNA was collected at the indicated time post CHX treatment.
Northern blots were probed for RVFV N mRNA, the S segment genome, and 28S rRNA as a
loading control. (H) Quantification of RVFV N transcript in CHX treated samples as shown in G.
Mean±SD for ≥3 independent experiments; no time points were significantly different between
control and Dcp2-depleted cells. (I) Quantification of RVFV S segment genome in CHX treated
samples as shown in G. Mean±SD for ≥3 independent experiments; no time points were
significantly different.
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Figure 3.10. Additional controls for Figure 3.9. (A) GFP mRNA transcribed in vitro was capped
with P-32 GTP, and digested or mock treated with terminator exonuclease in the presence or
absence of Drosophila cellular RNA as indicated. RNA was run under denaturing conditions,
transferred to a nitrocellulose membrane and radioactivity was quantified using ImageQuant.
Mean of 2 experiments +/- SD. (B) Drosophila cells were treated with the indicated dsRNA for 3
days, then infected with RVFV (MOI 0.01) and processed for immunofluorescence. Percent
infection was quantified and normalized to non-targeting control. Mean±SD of ≥3 independent
experiments; n.s. = not significant. (C) Quantification of northern blot analysis from Drosophila
cells treated with the indicated dsRNA and infected with RVFV. Northern blots were probed for
RVFV N and normalized to 28S rRNA levels. Mean±SD of ≥3 independent experiments; n.s. =
not significant. (D) DL1 cells were pretreated with the indicated dsRNAs, infected with RVFV and
subject to the exonuclease assay. Northern blots were quantified and the ratio of digested RVFV
N mRNA divided by the mock treated sample, yielding the ratio of mRNA that is refractory to
digestion. Mean±SD for ≥3 independent experiments; n.s. not significant.
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Figure 3.11. Cell cycle RNAs are an enriched substrate for RVFV cap-snatching.
(A) Pie chart of annotated GO function of sequences from the 5’ end of RVFV mRNAs mapped to
Drosophila. (B) Quantitative RT-PCR of levels of indicated target mRNAs, normalized to RP49 as
a cellular loading control, and shown as fold change over non-targeting dsRNA (luciferase).
Mean±SD for ≥3 independent experiments; *p<0.05 (C) Schematic representing position of RTPCR primers utilized in D. Forward primers recognizing the first 11 nucleotides of the host gene
5’UTR were used amplify Host-RVFV fusion mRNA, and internal primers were used to amplify
total RVFV N mRNA. (D) Quantitative RT-PCR of the indicated Host-RVFV N mRNA conjugates,
normalized to RP49 as a loading control, and shown as fold change over non-targeting dsRNA
(luciferase). Mean±SD for ≥3 independent experiments; *p<0.05 (E-G) Cells expressing Dcp1GFP, to monitor P bodies, were treated with the indicated dsRNA for 3 days, fixed, imaged and
analyzed using MetaXpress software. Mean±SD for ≥3 independent experiments; n>500 cells;
*p<0.05. (E) Average nuclear area shown relative to luciferase control. (F) Average Dcp1-GFP
foci size relative to luciferase control. (G) Average number of Dcp1-GFP foci per cell relative to
luciferase control.
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Figure 3.12. Endogenous sequences cap-snatched by RVFV in Drosophila. List of capsnatched sequences, their length and corresponding Drosophila gene. GO terms are shown and
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Figure 3.12 (cont.): color-coded to the pie chart in Figure 3.11A. Genes that were independently
identified in multiple experiments are filled purple.
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Figure 3.13. Cell cycle arrest in late S/early G2 phase enhances bunyavirus replication.
(A) Representative images of DL1 cells treated with the indicated dsRNA, infected with RVFV for
30 hours, fixed and stained for RVFV N protein (green) and total nuclei (blue). (B) Quantification
of cells treated with the indicated dsRNA, then infected with either RVFV or VSV for 30 or 24
hours respectively. Mean±SD for ≥3 experiments shown; *p<0.05. (C) Cells were treated with the
indicated cell cycle gene dsRNA. Quantification of northern blot analysis of RVFV N mRNA
normalized to dRPS6 with the mean±SD for ≥3 experiments shown; *p<0.05. (D) Quantitative RTPCR for 5’His3-RVFV N fusion mRNA in cells treated for the indicated dsRNA for 3 days, and
then infected with RVFV for 30 hours. Mean±SD for ≥3 experiments shown; *p<0.05. (E) DL1
cells treated with the indicated dsRNA and infected with LACV for 72 hours. Quantification of
northern blot analysis of LACV N mRNA and S segment genome/anti-genome normalized to
dRPS6 with the mean±SD for ≥3 experiments shown; *p<0.05.
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Figure 3.14. Representative northern blots as in Figure 3.13. (A) Representative northern blot
of DL1 cells treated with the indicated dsRNAs and infected with RVFV for 30 hours quantified as
in Figure 3.13C. (B) Representative northern blot of DL1 cells treated with the indicated dsRNA
and infected with LACV for 72 hours quantified as in Figure 3.13E.
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Figure 3.15. Ectopic expression of Dcp2 restricts RVFV replication.
(A) Control cells or cells expressing myc-Dcp2 were treated with the indicated dsRNA for 3 days,
infected with RVFV for 30 hours and analyzed by immunoblot. (B) Cells were treated and infected
as in A, processed for immunofluorescence and quantification of the percent infection with the
mean±SD for ≥3 experiments shown; *p<0.05. (C) Cells were treated as described in A and
infected with VSV for 24 hours. Cells were processed for microscopy and quantification of the
percent infection with the mean±SD for ≥3 experiments shown; n.s. not significant.
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IV. THE MRNA DECAPPERS DCP2 AND NUDT16 LIMIT DISTINCT BUNYAVIRAL
CAP-SNATCHING TARGETS TO RESTRICT INFECTION IN HUMANS

1. Background
Bunyaviruses are a genus of negative sense tripartite RNA viruses that infect
diverse species, including plants and animals, and are largely vectored to vertebrate
animals by arthropods, typically mosquitoes or ticks (16). Since these viruses have
evolved to replicate in such disparate hosts, they likely hijack deeply conserved
biological mechanisms to replicate. Previously, we found that two mosquito-transmitted
bunyaviruses, the orthobunyavirus LaCrosse virus (LACV) and the phlebovirus Rift
Valley Fever virus (RVFV), are restricted by the cellular RNA decapping machinery in
insects (60). In a genome-wide RNAi screen to examine cellular factors impacting RVFV
replication in Drosophila, we identified the canonical mRNA decapping enzyme, dDCP2,
and two activators of decapping, Me31B (DDX6/Rck) and dLSM7, as antiviral against
RVFV. Mechanistically, we found that mRNA decapping restricts the availability of
cellular mRNA substrates used by these viruses for viral cap-snatching, a unique
mechanism of viral mRNA transcription in which the 5’ cap and 10-18 nucleotides (nt) of
a host mRNA are used as an initiating primer for viral mRNA transcription. Moreover, we
found that cell cycle mRNAs, which are under tight control by the decapping machinery,
are the preferential targets used by RVFV, explaining the tight bottleneck imposed by
dDCP2.
Since bunyaviruses also cap-snatch in vertebrates, we examined whether
decapping is a conserved mechanisms of viral restriction in humans. While lower
organisms from yeast to insects encode only one known decapper, DCP2, decapping is
more complex in vertebrates (44). At least two mRNA decapping enzymes have
61

decapping activity in mice and humans, DCP2 and NUDT16 (117). DCP2 is the direct
homolog of yeast and insect DCP2, while there are no clear homologs of NUDT16 in
Drosophila. Recent studies have suggested that NUDT16 and DCP2 have both
redundant and specific decapping targets, and they are thought to be downstream of
specific RNA decay pathways (76). While microarray profiling has identified panels of
DCP2 and NUDT16 sensitive targets in murine cells (76) and immunoprecipitation of
human DCP2 has identified some RNA targets (78), the endogenous mRNA targets of
human NUDT16 and what overlap they may possess with human DCP2 are largely
unknown. Additionally, it is unclear how targets are differentially targeted to these
enzymes and whether they share similar mechanisms of activation.
Since dDCP2 restricts RVFV in insects by decapping RVFV targets, we set out to
determine if decapping also presents a bottleneck for RVFV replication in human cells.
Indeed, we find that depletion of either DCP2 or NUDT16 led to increased RVFV
replication, and enforced expression of either decapper also restricted viral replication.
Since either loss of function or gain of function impact RVFV infection, these data
suggest that DCP2 and NUDT16 are limiting in the cell. By sequencing snatched
endogenous targets, we found that some targets were restricted specifically by either
DCP2 or NUDT16, while others were restricted by both decappers. This suggests that
RVFV cap-snatches in a niche where both DCP2 and NUDT16 are present. It is known
that DCP2 resides in Processing (P) bodies, RNA-protein (RNP) complexes within the
cytoplasm that contain the majority of RNA decay enzymes, including DCP2 and its
known activators (44), and we previously showed that dDCP2 and the RVFV capsnatching machinery colocalize in the cytoplasm. Minimal data regarding the localization
of NUDT16 within the cytoplasm exists, and overexpression and endogenous antibodies
have shown both punctate and diffuse cytoplasmic staining (81, 117). We find that in
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addition to DCP2, NUDT16 is present in cellular granules indicative of P bodies. This
indicates that RVFV cap-snatches in P bodies from DCP2 and NUDT16 targets.
Intriguingly, we also find that RVFV infection leads to a loss of P body granules. This
suggests that decapping may be activated as an antiviral mechanism to combat
bunyaviral infection in humans. Overall, our data demonstrate a competition between
RVFV cap-snatching and the cellular mRNA decapping machinery for the same pool of
mRNA targets, and that these targets are limiting for viral replication. Furthermore, we
identified bona fide targets of RVFV cap-snatching in humans, which are highly enriched
for ribosomal proteins and other translationally related RNAs. Altogether, we
demonstrate a conserved role for mRNA decapping in RVFV restriction and suggest that
DCP2 and NUDT16 have both common and unique niches and targets that overlap with
virally-targeted mRNAs.

2. Results

Multiple mRNA decappers restrict Rift Valley Fever virus in human cells
Since arboviruses, including bunyaviruses, replicate in Plants and in Animals
from insects to humans (16), we set out to determine whether our finding that RVFV is
restricted by dDCP2, the sole decapper in insects (61), is conserved in humans. We
performed siRNA knockdown of the known mRNA decappers in humans, DCP2 and
NUDT16 (118). While we only achieved modest knockdown at the mRNA level as
measured by RT-qPCR (Figure 4.1A, B), we found that depletion of either DCP2 or
NUDT16 lead to a significant increase in the relative infection of RVFV in U2OS cells, as
measured by the percentage of infected cells (~2-fold; Figure 4.1C). DDX6/Rck is a
known activator of DCP2-dependent decapping (35, 46) and restricts RVFV in insects
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(61), and thus we also tested whether depletion of this factor impacted infection. Indeed,
we found, similar to the effects seen with depletion of the decapping enzymes, a two-fold
increase in the relative percentage of infected cells upon DDX6 depletion (Figure 4.1C).
These data suggest that mRNA decapping is a broadly conserved pathway that restricts
RVFV replication from insects to humans.
Our previous findings that decapping restricts bunyaviral replication at the level of
RNA transcription in insects led us to examine whether RNA levels are increased in
RVFV infected cells depleted of decapping enzymes. We found, similar to
immunofluorescence studies, that total viral RNA levels are significantly increased upon
depletion of DCP2 or NUDT16 as measured by RT-qPCR (~2-fold; Figure 4.1D). Since
RT-qPCR does not distinguish the viral mRNA from the viral genomic RNA, future
studies will examine the effects of knockdown of decapping enzymes by northern blot,
as these RNA species can be distinguished based on size.

DCP2 and NUDT16 are limiting in human cells
We set out to determine whether ectopic expression of either decapping enzyme
could inhibit RVFV replication in humans. We established polyclonal stable cell lines
expressing either Flag-tagged NUDT16 (118) or GFP-tagged DCP2 (126) and compared
infection to control cells (Figure 4.2A, B). We observed low levels of these decappers
after selection that was detectable only by an ultra-sensitive Enhanced
Chemiluminescent (ECL) substrate capable of detecting protein in the low femtogram
level by immunoblot (Thermo Scientific SuperSignal West Femto Substrate) (Figure
4.2C, data not shown), suggesting that abundant overexpression of decapping enzymes
is deleterious in human cells.
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Despite these low levels of protein expression, we observed significantly reduced
levels of viral infection upon enforced expression of either DCP2 or NUDT16 compared
to control cells as measured by multiple assays. First, we found that ectopic expression
of DCP2 or NUDT16 significantly reduced the percentage of infected cells (Figure 4.2A,
B). Second, we measured levels of viral glycoprotein, Gn, by immunoblot, and found that
viral protein was significantly reduced in the presence of low-level enforced expression
of NUDT16 (Figure 4.2C). Third, we found significantly reduced viral RNA by RT-qPCR
with enforced NUDT16 expression (Figure 4.2D). This suggests that decapping is a
highly regulated process, and that decappers are limiting in human cells. Future studies
will examine the effects of enforced expression of DCP2 on viral protein and RNA.

Histone mRNAs are a conserved cap-snatching target of Rift Valley Fever virus
We previously found that RVFV primarily snatches dDCP2 targets, which are
largely cell-cycle-regulated mRNAs, for mRNA transcription, including replicating histone
mRNAs (60). Therefore, we tested whether replicating histone mRNAs (Histone 3 and
Histone 2A) are an endogenous target of RVFV cap-snatching in human cells. Thus, we
used a PCR strategy to capture the specific host mRNA snatched by RVFV using with a
forward primer against the first 11 nucleotides of the 5’UTR of our host gene of interest
and a reverse primer against the viral N mRNA transcript. Using this strategy, we find
that the histone mRNAs H2A and HIS3 are both targets of viral cap-snatching (Figure
4.3A, B). Interestingly, preliminary data show these target mRNAs appear to be
increased upon depletion of either DCP2 or NUDT16, although NUDT16 appears to
have a larger impact. Because either decapper impacts the levels of these mRNAs, our
data suggests redundancy in target specificity between these decapping enzymes. This
also suggests that decappers are limiting, since each enzyme is unable to fully
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compensate for the loss of the other in degrading this pool of mRNAs. This also
demonstrates for the first time that NUDT16 plays a role in the basal turnover of human
histone mRNAs (92, 121).
Additionally, we examined whether enforced expression of NUDT16 reduces the
levels of histone-viral mRNA conjugates. We found that both H2A- and His3-N
conjugates were significantly reduced by low levels of NUDT16 ectopic expression
(Figure 4.3C, D), similar to our observation of decreased total viral RNA (Figure 4.2D).
These data suggest that NUDT16 levels are tightly regulated, and that minor alterations
in their expression can profoundly affect the pools of transcripts used by bunyaviruses
for replication. Future studies will examine the effects of enforced expression of DCP2
on these RNA species.

RVFV primarily snatches translation related mRNAs, and these mRNAs are limited
by RNA decapping
We set out to determine the spectrum of mRNAs snatched by RVFV in human
cells using 5’RLM-RACE (60). We obtained 83 sequences of non-viral origin from the 5’
end of the viral N mRNA transcript (Table 4.1). The mean length of endogenously capsnatched sequences was 13.1nt (S.D. +/- 1.35), and sequences ranged in length from
10-18 nt, consistent with previous reports (17). There was little sequence preference in
the first 10nt of the snatched sequences, with the exception of a slight preference for a T
at position 2 (Figure 4.4A). There was a strong preference for the last nucleotide of the
snatched sequence before the initiation of the viral sequence to be a C or G (Figure
4.4B), and this was slightly influenced by the length of the sequence; sequences 12 or
15 nt in length had a strong C preference, while those 13-14 nt in length showed
increased G preference for a terminal G residue (Figure 4.4C). Thus, there is a strong
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bias for the RVFV polymerase to cleave endogenous host mRNAs following a residue
that base pairs with three hydrogen bonds.
Interestingly, of the 49 sequences we were able to match back to annotated 5’
UTRs in the human genome, we found a strong enrichment for genes involved in mRNA
translation, including RNAs encoding protein components of the ribosome and
translation initiation and elongation factors (Table 4.1) (Figure 4.4D). This is in contrast
with our previous findings in insects, where we found that cell cycle related messages
were preferentially incorporated into RVFV mRNAs (60). This suggests that specific
cohorts of genes are targeted during viral cap-snatching, and that these RNAs vary
between hosts. Potentially, these mRNAs may be in niches where cap-snatching and
RNA degradation overlap; future work will examine basal levels of these transcripts upon
perturbation of decapping to determine whether decappers are a driving force for
translational mRNA stability.
Of the endogenous targets observed, we examined the incorporation of two
ribosomal protein mRNAs, RPL37A and RPS3A, into viral mRNA conjugates. Similar to
histone mRNAs, incorporation of the 5’ end of RPL37A into viral mRNA was increased
by either DCP2 or NUDT16 depletion, suggesting that this mRNA is redundantly
degraded by these enzymes, but that in the absence of one, the other decapper is
unable to compensate (Figure 4.4E). However, we found loss of NUDT16 more
profoundly impacted incorporation than DCP2, suggesting potential target specificity. In
contrast to the redundancy on histone mRNAs, we found that RPS3A-viral RNA
conjugate levels were dramatically increased upon NUDT16 depletion, but were
unaffected by DCP2 depletion (Figure 4.4F). This suggests that RPS3A is a specific
target of NUDT16 decapping, and that it is stabilized upon NUDT16 depletion. Further
studies will examine the basal levels of these targets in uninfected cells depleted of
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decappers, and whether any of our other endogenously snatched targets are DCP2
specific in their manner of decay.

Rift Valley Fever virus infection triggers P body loss in human cells
DCP2 and other RNA decay machinery reside in cytoplasmic P bodies. We found
that RVFV nucleocapsid protein, N, co-localizes with dDCP2-containing P bodies in
insect cells, and Mir et al. have demonstrated that the bunyavirus Sin Nombre N protein
co-localizes with DCP1A-containing P bodies in human cells. Thus, we examined the
interplay between RVFV N and P bodies in human cells. First, we visualized P bodies as
a function of time post infection using the P body marker DDX6, which we have also
shown is a conserved antiviral factor ((60) and Figure 4.1C). Surprisingly, we found that
by 12 hours post infection, DDX6 positive punctae were lost in infected cells, but not in
neighboring uninfected cells in the same field (Figure 4.5A, B). Since DDX6, but not
DCP1A, can be found in related cytoplasmic RNPs called stress granules, we examined
DCP1A punctae during RVFV infection. We found that DCP1A positive punctae were
also lost during RVFV infection (Figure 4.5C, D).
The localization of NUDT16 in the cytoplasm has not been carefully studied; it is
unclear whether NUDT16 resides in P bodies, where DCP2 and known decapping
activators are present. Additionally, whether DCP2 and NUDT16 have overlapping
locations in the cell has not been examined. Due to technical issues, we were unable to
visualize endogenous DCP2 or NUDT16 localization in the cytoplasm to examine
whether: 1) these proteins are punctate in P bodies; 2) whether these punctae colocalize
with RVFV N; and 3) whether any punctae dissociate with RVFV infection. However,
preliminary studies examining Flag-NUDT16 did show distinct punctate cytoplasmic
staining, reminiscent of P bodies (Figure 4.5E). Future studies will clarify the localization
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of Flag-NUDT16 with DCP2 and other known P body markers basally and in the context
of RVFV infection.

P body depletion is not autophagy dependent
One possible mechanism that can potentially account for the loss of P bodies is
capture and degradation of these RNPs by autophagy (20). Autophagy is a highly
conserved process in which large materials, such as damaged organelles, are captured
by a double membrane structure termed an autophagosome, which then fuses with a
lysosome that releases its lytic enzymes to complete the degradation of its contents (82).
Stress granules are degraded through autophagy in a conserved manner from yeast to
humans, and basal levels of P bodies are increased in autophagy deficient yeast (20).
We set out to determine whether autophagy activation is responsible for the clearance of
P bodies in RVFV infected cells, as this could explain P body loss.
We found that in U2OS cells treated with siRNAs against the essential autophagy
proteins, ATG5 and ATG7, viral induced clearance of P body punctae was unaffected
(Figure 4.6A, B). Furthermore, we used ATG5 knockout MEFs, which cannot undergo
autophagy, and again observed no affect on P body clearance compared to wild type
MEFs (Figure 4.6C, D). These data demonstrate that RVFV-induced P body clearance is
independent of autophagy.

3. Discussion
Bunyaviruses infect widely disparate organisms from plants to insects to humans.
We previously found that dDCP2 creates a bottleneck of mRNA substrates for RVFV
cap-snatching in Drosophila (60). Since RVFV also infects mammals, including humans,
we set out to explore the role of decapping in RVFV infection in human cells. Recent
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studies have revealed the increased complexity of mRNA decapping in mammals, and
unlike yeast and Drosophila, where only one mRNA decapper is known, at least two
decappers exist in mammals (118). Interestingly, the specificity of these decappers is
only beginning to be unraveled (76). We found that decapping is a conserved
mechanism by which cells restrict bunyaviruses. We found that depletion of either DCP2
or NUDT16 led to increased RVFV replication, demonstrating a lack of redundancy in
their activity and an inability to fully compensate for loss of one another. This is in line
with previous data showing that these enzymes may have both redundant and specific
endogenous targets and functions within specialized RNA decay pathways (76). Indeed,
we found that RVFV snatching of RPS3A mRNA is increased upon loss of NUDT16 but
not DCP2, while RPL37A mRNA is increased upon loss of either DCP2 or NUDT16. This
demonstrates both specific and overlapping dependencies.
While it was known that DCP2 resides in P bodies from yeast to humans, the
localization of NUDT16 within the cytoplasm was unknown. We found that these
decappers reside in the same compartment where RVFV N is targeting mRNAs.
Preliminary data suggest that in the context of enforced expression, Flag-NUDT16 forms
cytoplasmic puncta (Figure 4.5E); these may be indicative of P bodies, and further work
will examine the spatial localization of NUDT16 in relation to other P body components.
As we and others have previously found that P bodies are not of uniform composition
(111, 141), even among the binding partners dDCP2 and dDCP1A in insects (61), the
possibility exists that NUDT16 and DCP2 specificity and redundancy could be explained
by differential targeting of RNAs to P bodies containing individual or both decappers.
While mechanistically it is unknown how specific mRNAs are targeted, it is possible that
decapping activators, which are known to bind RNA, provide some level of specificity.
These may either bring mRNAs to P bodies in general or perhaps to specific decappers.
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Since little is known about NUDT16, and it is not conserved in yeast where most
decapping activators were first identified, it is possible that there exist decapping
activators that specifically impact NUDT16 function. Future work will examine the
composition of these compartments to attempt to understand how RNAs are targeted to
them. Indeed, there may be additional uncharacterized decappers in mammals. A recent
report by Song et al. using in vitro decapping assays identified six additional NUDIX
domain containing proteins in mice with decapping activity (119).
We found that RVFV preferentially cap-snatches mRNAs associated with
translation and that the decappers restrict the incorporation of these mRNAs into viral
transcripts. Indeed, we found seven ribosomal protein mRNAs, one translation initiation
factor and one elongation factor. This suggests that this cohort of functionally related
mRNAs is coordinately regulated post-transcriptionally by decapping. RNA operons have
been defined as pools of functionally related genes that are coordinately regulated posttranscriptionally by sequence specific RNA binding proteins. While some RNA operons
are well defined (e.g. histone mRNA stability regulated by stem loop binding protein),
others have only suggestive evidence (69). Intriguingly, some of the best evidence for
the coordinated regulation of functionally related genes at the level of mRNA stability
comes from studies of immune-related gene programs. The mammalian RNA binding
proteins ELAV/Hu and TTP target chemokine and cytokine mRNAs to promote their
stability, and the half-lives of these RNAs are synchronously altered during immune
responses (69). Other evidence for functionally coordinated decay operons comes from
microarray data examining the half-lives of RNA transcripts in yeast; functionally related
genes, especially those within the same complex, have similar half-lives (137). Indeed,
one of the complexes demonstrating a high degree coordination in the decay rate of its
components is the ribosome (137). This suggests that the directed decay of translation
71

related mRNAs is deeply conserved. Overall, these findings imply that decapping
activation could be a useful tool to regulate RNAs through targeted RNA decay, or that
inhibition of decapping could dramatically stabilize these programs.
Our findings that translation related mRNAs are preferentially snatched during
RVFV infection are intriguing; if cap-snatching and RNA decapping are indeed
competing processes, this suggests a high level of targeted degradation of these
translational mRNAs. mRNAs encoding the core translational machinery, such as
ribosomal proteins, are known to have 5’Terminal Oligopyrimidine (TOP) motifs,
consisting of cytosine- and uridine-rich stretches greater than 4 bases at the extreme 5’
end of the mRNA (5). The translation and polysome occupancy of TOP motif containing
mRNAs has been shown to be coordinately regulated in response to mTOR inhibition
(123). We hypothesize that upon RVFV infection, translation related mRNAs are
specifically targeted for degradation by decapping as a means to restrict translation of
viral RNAs to combat infection within the cell. Indeed, many known antiviral programs
shutdown translation (37, 68). PKR inhibits translation through the phosphorylation of
EIF2A, but its activity is blocked by RVFV (63). IFIT proteins are interferon-induced and
inhibit translation initiation at multiple steps, however, RVFV does not induce interferon
efficiently (10). Additionally, as bunyaviruses have evolved an encoded ability to recruit
ribosomes without the aid of the EIF4F complex and can recruit the 43S pre-initiation
complex via their nucleocapsid protein (84), this suggests ancient evolutionary pressure
to find novel means of ribosome recruitment and translation. As these viruses steal
endogenous caps, which should not stimulate an immune response, the need to develop
this activity is not obvious. DCP2 is potentially inducible by interferons (109) in humans
and by poly I:C and lentiviral infection in murine cells (75), Thus, decapping of translation
mRNAs may potentially be a novel innate immune effector response. Future work will
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examine whether the stability of these mRNA targets is affected by perturbation of
decapping basally in uninfected cells, to see if this targeted degradation is indeed
triggered as a host response to viral infection.
Since only subtle increases in the levels of decappers are sufficient to attenuate
RVFV replication, this suggests that decapping activation may be a reasonable
therapeutic target to restrict bunyaviral infection. The potential to harness decapping as
an antiviral mechanism or as a tool to control the expression of specific cohorts of genes
is exciting. As theoretically druggable targets, decapping activation could be a novel
mechanism for targeted gene regulation in multiple contexts. 	
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Figure 4.1. RVFV replication is increased by depletion of human mRNA decapping
enzymes in U2OS cells. (A) RNA collected from U2OS cells treated with two pooled siRNAs
targeting DCP2 three days post transfection was analyzed by RT-qPCR for knockdown efficiency.
Fold change is normalized to GAPDH (n=1). (B) Cells were treated as in A with siRNAs targeting
NUDT16 and analyzed by RT-qPCR for knockdown efficiency. Fold change is normalized to
GAPDH (n=1). (C) U2OS cells were treated with the indicated siRNAs and then infected with
RVFV (strain MP12, MOI=0.4) for 18 hours. Cells were fixed and stained for total nuclei and
RVFV N protein by immunofluorescence. Automated image analysis was used to determine the
percentage of infected cells. Relative infection is shown (n=3, *p<0.05). (D) U2OS cells were
treated with the indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected
20hpi and analyzed by RT-qPCR for RVFV N RNA. Fold change is normalized to GAPDH (n=3,
*p<0.05).
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Figure 4.2. mRNA decapping enzymes are limiting for RVFV infection in humans. (A) U2OS
cells or stable U2OS cell lines overexpressing GFP-tagged DCP2 were infected with RVFV
(MOI=0.4). Cells were fixed and stained for total nuclei and RVFV N protein by
immunofluorescence. Automated image analysis was used to determine the percentage of
infected cells. Relative infection normalized to control cells is shown (n=3, **p<0.01). (Figure
4.1A, B) U2OS cells or stable U2OS cell lines overexpressing Flag-tagged NUDT16 were
infected with RVFV (MOI=0.4). Cells were processed as in A. Relative infection normalized to
control cells is shown (n=3, **p<0.01). (C) Control cells or cells expressing Flag-tagged NUDT16
were infected with RVFV (MOI=1) and total protein was collected 20 hpi and analyzed by
immunoblot. A representative of three experiments is shown. (D) Control cells or cells expressing
Flag-tagged NUDT16 were infected with RVFV (MOI=1) and total RNA was collected 20 hpi and
analyzed by RT-qPCR for RVFV N RNA. Fold change is normalized to GAPDH (n=3, **p<0.01).
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Figure 4.3. Histone mRNAs are incorporated into RVFV RNAs and limited by decapping.
(A) U2OS cells were treated with the indicated siRNAs and then infected with RVFV (MOI=1).
Total RNA was collected 20hpi and analyzed by RT-qPCR for RVFV H2A-N mRNA conjugates.
Fold change is normalized to GAPDH (n=3, *p<0.05). (B) U2OS cells were treated with the
indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected 20hpi and
analyzed by RT-qPCR for RVFV HIS3-N mRNA conjugates. Fold change is normalized to
GAPDH (n=3). (C) Control cells or cells expressing Flag-tagged NUDT16 were infected with
RVFV (MOI=1) and total RNA was collected 20 hpi and analyzed by RT-qPCR for RVFV H2A-N
mRNA conjugates. Fold change is normalized to GAPDH (n=3, *p<0.05). (D) Control cells or cells
expressing Flag-tagged NUDT16 were infected with RVFV (MOI=1) and total RNA was collected
20 hpi and analyzed by RT-qPCR for RVFV HIS3-N mRNA conjugates. Fold change is
normalized to GAPDH (n=3, **p<0.01).
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Figure 4.4. Ribosomal and translationally related mRNAs are targeted by both RVFV capsnatching and mRNA decapping. (A) LOGO analysis of the first 10 nt of 83 clones showing
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Figure 4.4 (cont.): sequence preference of RVFV cap-snatching. Preference for a base is shown
as a function of letter size. (B) LOGO analysis of the last 10 nt of 83 clones showing sequence
preference of RVFV cap-snatching. Preference for a base is shown as a function of letter size.
(C) LOGO analysis of 83 full-length sequences showing sequence preference of RVFV capsnatching. Preference for a base is shown as a function of letter size. (D) Analysis of enrichment
of 49 snatched sequences by cellular GO term. Enrichment of functional categories is shown as a
function of P value. (E) U2OS cells were treated with the indicated siRNAs and then infected with
RVFV (MOI=1). Total RNA was collected 20hpi and analyzed by RT-qPCR for RVFV RPL37A-N
mRNA conjugates. Fold change is normalized to GAPDH (n=3, *p<0.05). (F) U2OS cells were
treated with the indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected
20hpi and analyzed by RT-qPCR for RVFV RPS3A-N mRNA conjugates. Fold change is
normalized to GAPDH (n=3, *p<0.05).
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Figure 4.5. RVFV infection triggers loss of Processing bodies in human cells. (A) U2OS
cells were infected with RVFV (MOI=1) at 14C and virus was allowed to bind for 1 hour; cells
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Figure 4.5 (cont.): were then washed and incubated at 37C for 11 hours. Cells were fixed and
stained for Rck/DDX6 (green), RVFV N protein (red) and total nuclei (blue). (B) Quantification of
Rck punctae in uninfected versus RVFV infected cells as shown in A. (**p<0.01, n=1). (C) U2OS
cells were treated and infected as in A. Cells were fixed and stained for DCP1a (red), RVFV N
protein (green) and total nuclei (blue). (D) Quantification of DCP1a punctae in uninfected versus
RVFV infected cells as shown in C. (**p<0.01, n=1). (E) Flag-NUDT16 expressing U2OS cells
were processed and stained with Alexa-488 conjugated anti-Flag (green) and for total nuclei
(blue). A representative image is shown.
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Figure 4.6. RVFV-dependent P body clearance occurs independent of autophagy. (A) U2OS
cells were transfected with the indicated siRNAs and infected three days post transfection with
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Figure 4.6 (cont.): RVFV (MOI=1) at 14C; virus was allowed to bind for 1 hour. Cells were then
washed and incubated at 37C for 11 hours. Cells were fixed and stained for Rck/DDX6 (green),
RVFV N protein (red) and total nuclei (blue). (B) Quantification of Rck punctae in uninfected
versus RVFV infected cells as shown in A. (**p<0.01, n=1). (C) WT or ATG5-/- MEF cells were
infected with RVFV (MOI=1) at 14C; virus was allowed to bind for 1 hour. Cells were then washed
and incubated at 37C for 11 hours. Cells were fixed and stained for Rck/DDX6 (green), RVFV N
protein (red) and total nuclei (blue). (D) Quantification of Rck punctae in uninfected versus RVFV
infected cells as shown in C. (**p<0.01, n=1).
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Snatched sequence (5' to 3')
CTTTCTGGGCTCAC
CTTTTCATTCCC
TCTGACCAGCACC
CGCCACCGTCGTC
CGCGTCGCTAGC
ACGGCCAGGTTGGGT
ACTTCCGGTTCCCG
CTCTTCCGCCGTCAC
GTTTTGCAGACGC
AAGCGTTGGGTGAC
CTCTGCCACTCTCG
CTTTTTCGCA
TGGCCCCAGCGGTG
CTCAGCAGCCAG
TTCTCTCTCGGC
CAGACCGCCGAGG
CTCTCGCCAGGC
GCGGAGCCGCG
CACTCGTGTCTC
CTTTTCTCTCTC
AGTGTGAGGGGC
CTCGGCAGCCGC
GGCGCAGAGGCCTGC
CCCCTCTCTGTCTT
ACTTGGCTTCAAAGC
AGCTGGCCAGGTC
CTCTTTCGCTCAGG
GTTTTTCCAAAG
GTTTCGCCTCAGG
TTTCTGCCCGTGGACG
AGGAGCGTAGAGGC
TTCTGGCGCGGAG
AGAGTCCGAGCCG
CTCTTTCCAGCCAGC
CCCTTTCCTCAGC
AGTGCGGGGTCGGC
GTTTTGCAGACG
CGCCTGGACGCAG
AGTAGCAGCAGCG
CTCTTCCGCCGCC
GCTGCCGCCGTCGC
CTCTTTCCCTTC
CCCAGACCAGC
ACAAAGCCCAGACG
AGAGCCGCCATC
CTTGGAGAAGCAAG
AGCCGCTGCGCCCGAG
TTAGCGACTATTGC
ACCGACCAAAATGGC

Official Gene Symbol
RPL37A
C17orf76-AS1
RPS3A
KRT8
NDUFS5
AGL
MTRF1L
EEF2
PPIA
LOC339240
TTC28
EEF1A1
IWS1
DDHD2
EIF3C
PCBP1
RPLP0
HDAC1
BEX1
BET1
NOMO1
SNX29
HBS1L
DESI1
CDK1
LOC541473
RPS23
DLEU7-AS1
DERL1
HNRNPA1
FAF2
MARCKSL1
CUL3
RPS8
RPLP1
CTSZ
PPIA
FXYD5
TPRXL
RABGGTA
CADM2
RPL10
PCBP2
HNRNPM
ARF1
GPR61
THBS1
REXO2
ETAA1

Table 4.1. Cap-snatched sequences mapped back to human 5’UTRs.
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V. CONCLUDING REMARKS

1. Summary
With climate change increasing the natural range of biting-insect vectors and the
encroachment of human development into the habitat of reservoir species, arboviruses
are an increasing threat to human health and agriculture worldwide. The lack of antiviral
therapeutics and vaccines against these pathogens necessitates that we increase our
understanding of their host requirements and immune evasion in order to combat these
diseases. Additionally, the unique lifecycle of arboviruses provides an excellent tool to
probe deeply conserved biological pathways and how these viruses interact to subvert or
utilize these functions. To this end, we have performed a genome-wide RNAi screen in
Drosophila cells to understand the virus-host interactions of the mosquito-transmitted
bunyavirus, Rift Valley Fever virus, and extended these findings to human studies.
Our genome-wide RNAi screen identified 131 host factors that impact the
replication of RVFV (strain MP12) in Drosophila. We found 124 factors that, when
depleted, allowed for increased infection, including multiple members of the 5’ to 3’ RNA
decay pathway: dDCP2, the canonical mRNA decapping enzyme, and two known
activators of decapping, Me31B/DDX6 and dLSM7. Additionally, we identified 7 factors
whose presence was necessary for efficient viral replication, including Rab5C, which has
been previously validated as a required factor for bunyaviral entry (45); taken together
with our previous finding that SUPT5H, another antiviral factor present in our gene set, is
antiviral against other arboviruses in Drosophila (143), the results of this screen have
both validated former knowledge of arboviral replication and enriched our understanding
of RVFV-host interactions in insects.
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As viruses have evolved unique mechanisms of hijacking host factors, unusual
molecular structures have evolved to decoy and recruit host proteins. Concomitantly,
cells have also evolved ways to detect and destroy these Pathogen Associated
Molecular Patterns (PAMPs). One such molecular signature are the unusual RNA
species made during viral infection that are not normally found in cells, especially in the
case of RNA viruses. A variety of host proteins exist to detect and destroy these unusual
RNAs throughout distantly related species. The RNAi silencing machinery in particular
has been shown to be potently antiviral in plants and insects, and some viruses have
even evolved ways to subvert this pathway. It is possible that other host pathways of
RNA decay are utilized in an antiviral fashion, in addition to their basal metabolic
functions within the cell. There has been recent increased interest in the understanding
of the interaction between viral replication and RNA decay factors. Interactions have
been demonstrated between 5’ to 3’ decay machinery and mosquito-transmitted
flaviviruses, such as West Nile virus (WNV) and Dengue virus (DENV). XRN1 and
DDX6, which we found to be antiviral factors for RVFV replication, have been shown to
be recruited to viral replication sites and required for efficient WNV replication (24), and
DDX6 has been shown to bind to DENV viral RNA to facilitate replication (138). These
data, along with our finding that VSV and SINV replication are not effected by RNA
decapping, suggest that bunyaviral replication is specifically restricted by the RNA
decapping machinery.
I demonstrated that RNA decapping in insects restricts bunyaviruses indirectly by
creating a bottleneck of mRNA substrates available for cap-snatching. Rather than
directly decaying viral RNA species, I found that dDCP2 does not affect viral mRNA capstatus or stability. Rather, dDCP2 restricts infection through the basal metabolism of its
own RNA substrates. Immunofluoresence studies revealed that the viral N protein,
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essential for cap-snatching, colocalizes with dDCP2 to a high degree in cytoplasmic
punctae. Furthermore, profiling of endogenously cap-snatched host messages revealed
that these RNAs are stabilized by dDCP2 depletion. Taken together, these results
indicate competition between cap-snatching and decapping for a common pool of
mRNAs. Additionally, I demonstrated that this restriction is conserved in whole animals
(flies) and in mosquito cells in tissue culture and against the distantly related bunyavirus,
La Crosse, suggesting that in insects decapping is broadly antiviral and that capsnatching is an important bottleneck for bunyaviral replication.
Interestingly, sequencing of cap-snatched targets also revealed a preference for
cell-cycle-related mRNAs in insects. In line with previous data from humans (144), I
showed that P body dynamics are intricately linked to the cell cycle, and that as cells
exist S phase and enter G2, P body size and number are significantly increased. This
presumably occurs due to the need to degrade mRNAs encoding for DNA replication
machinery and cell cycle progression, including replicating histone mRNAs, which are
targeted to processing bodies for degradation by decapping. I found that arresting the
cell cycle at S/G2, a stage when P bodies are large and enriched for cell cycle mRNAs,
dramatically increased RVFV and LACV replication. Indeed, our genome-wide screen
identified 28 factors that increased RVFV infection and whose depletion arrests the cell
cycle at S/G2. Intriguingly, previous reports have found that in human cells, RVFV
causes cell cycle arrest in S phase late during infection and that this cell cycle arrest is
advantageous for viral output (6). As the link between P body dynamics and the cell
cycle is conserved from insects to humans, I hypothesize that S phase arrest assists
RVFV replication through increased targeting of cell cycle mRNAs to P bodies, where
they are cap-snatched (Figure 5.1). It has been demonstrated that this cell cycle arrest
during viral replication is due to viral activation of the DNA damage response (in spite of
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a demonstrated lack of DNA damage during infection) and that chemical inhibitors of this
pathway prevent cell cycle arrest and decrease viral replication (6), suggesting that
prevention of cell cycle arrest may be a potential therapeutic for RVFV infection.
In mammals, such as mice and humans, at least two distinct cytoplasmic
decapping enzymes have been described (117). I demonstrated that both DCP2 and
NUDT16, the newly described and more widely expressed decapping enzyme, are
antiviral against RVFV in humans. Through both siRNA and overexpression studies, I
found that both DCP2 and NUDT16 affect RVFV replication, even with modest levels of
depletion or enforced expression. This suggests that RVFV cap-snatches from a
common pool of mRNAs targeted by these decappers. Additionally, it suggests that
mRNA decapping is under tight regulation, as I see effects on viral replication with low
levels of perturbation, and as stable cell lines self selected for cells with low levels of
enforced decapper expression.
While both decapping enzymes are capable of restricting RVFV infection,
profiling of endogenously cap-snatched targets in human cells revealed interesting
effects of individual decappers on endogenous targets. I found that some targets are
shared by both DCP2 and NUDT16 and that depletion of either causes increased
incorporation of these targets into viral conjugates; interestingly, neither decapper
appears able to compensate for the loss of the other, again suggesting that these
enzymes are limiting and tightly regulated. Other targets, such as the ribosomal protein
mRNA RPS3A, are degraded exclusively by one decapper; while NUDT16 depletion
increased the incorporation of RPS3A into viral conjugates, DCP2 knockdown had no
effect. This suggests that these enzymes have both redundant and specific mechanisms
by which they are activated or through which mRNAs are targeted to them. This may
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also suggest both overlapping and specific localization and compartments, which
warrants further investigation.
While I did see evidence of cell cycle related mRNAs being endogenously capsnatched, unlike insect cells, where the primary mRNA targets of viral cap-snatching
were cell cycle related, in humans I showed that predominantly, mRNAs related to host
mRNA translation were cap-snatched. Intriguingly, during many viral infections in human
cells, the host responds by shutting down translation; it has been demonstrated that
other bunyaviruses, such as the hantavirus Sin Nombre, encode their own translational
initiation activity in the N protein (84). I hypothesize that viral cap-snatching in humans
primarily targets translation related mRNAs because they are being targeted for
degradation by the host during infection, and that these mRNAs are targeted to areas
where both decappers and the cap-snatching machinery compete (Figure 5.2). To this
end, I also found that viral infection triggers loss of visible P bodies as measured by
multiple markers. It has been demonstrated that some viruses can target stress granule
or P body components for degradation or relocalization, thus inhibiting their formation
(24, 39), however I found that protein levels of these markers (Dcp1a, Rck/DDX6) and
for DCP2 itself are stable during infection, suggesting that some other mechanism
causes these morphological changes (data not shown). Activation of decapping could
account for these results, as increasing degradation of nucleating mRNAs would lead to
the dissociation of microscopically visible punctae. It is also possible that P body mRNAs
are limiting enough that viral cap-snatching itself accounts for a decreased ability of P
bodies to nucleate. Early work examining the effects of RNA stability during bunyaviral
infection demonstrated that RNAs have rapidly decreasing half-lives during LACV
infection, and that even more stable mRNAs, such as actin, are degraded at an
increased rate (104). It was shown that these effects continue, even if viral transcription
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is halted by cycloheximide treatment (104), suggesting that RNA instability is
independent of viral cap-snatching and perhaps is the result of increased decapping
activity during infection.
Overall, this work advances our understanding of 5’ to 3’ RNA decay and mRNA
decapping from insects to humans. We demonstrate that specific pools are targeted by
5’ to 3’ RNA degradation, rather than all RNAs, and we hypothesize that these pools are
malleable depending on cellular context. Additionally, we find that specific pools of RNAs
involved in particular programs (the cell cycle in insects and translation in mammals) are
the targets of RVFV cap-snatching during infection and that these RNA pools overlap
with decapping targets. This work further demonstrates that intricate interactions exist
between RNA virus replication and RNA decay pathways and suggests that RNA decay
components may be potential targets for therapeutic intervention in the treatment of RNA
viral disease.

2. Future Directions
While we focused on the interplay between mRNA decapping and viral
transcription in our genome-wide RNAi screen, which included P body resident proteins
and cell cycle genes, we also validated a large number of additional genes that impact
RVFV infection. We identified two genes with roles in transcriptional pausing, dSUPT5H
and dSUPT6H, which likely regulate the anti-RVFV transcriptional program, as we
recently found that pausing controls antiviral defense against diverse viruses, including
RVFV (143). Future studies can explore whether the other genes involved in
transcription or splicing that we identified regulate antiviral gene expression programs in
insects. Furthermore, we identified 6 of the 7 core components of the COPI coatamer as
antiviral. COPI is involved in retrograde transport between the golgi and endoplasmic
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reticulum, impacting secretion (Figure 3.2, Table 6.1). Although viral budding and egress
would be attenuated by blocking secretion, the screen was not dependent on these
processes, and therefore, it is unlikely that these steps are involved in the restriction.
Furthermore, our readout for infection is expression of a cytoplasmic protein
(nucleocapsid), suggesting that retrograde transport likely restricts viral infection prior to
translation. Many RNAi screens have identified the COPI coatamer as required for
infection, at the level of entry (19, 70) or RNA replication (31, 98), and thus we have
potentially uncovered a new aspect of COPI-virus interactions. Further studies will reveal
how COPI and the other genes identified impact RVFV replication.
In this gene set, we also identified 40 core components of the ribosome, six
genes impacting ribosomal biogenesis and 45 genes with overall impacts on translation
as antiviral. While human cells shut down translation in an attempt to combat some viral
infections, we found that knockdown of translational factors in insects actually increases
infection. Inhibition of translation via polysome disassembly has been shown to increase
P body size in Drosophila cells (42). I hypothesize that knockdown of translational
factors leads to increased mRNA targeting to P bodies, thus increasing P body size and
number in a manner consistent with cell cycle arrest. Future studies will confirm whether
this panel of genes indeed affects P body morphology; if not, clarification of the
interactions between the translational pathway and RVFV in insects should be further
dissected, especially since we find particular targeting of ribosomal protein RNAs for
viral cap-snatching in human cells.
Our screen set out to identify factors effecting RVFV replication, which led to the
discovery that cell cycle mRNAs are targets of both viral cap-snatching and dDCP2dependent decapping. This suggests pools of cell cycle RNAs are under precise control
by dDCP2 in insects; how these particular mRNAs are targeted to dDCP2 remains
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unknown. Furthermore, increasing evidence suggests that P bodies are not
compartments of uniform composition, rather they may possess potential specializations
since P body components only partially overlap and can be in separate structures (111,
141). Indeed, my own studies found that while dDCP2 tightly co-localizes with RVFV, the
canonical binding partner of dDCP2, dDCP1A only partially co-localizes with either
dDCP2 or RVFV N (61). It is likely that in addition to specialization in their protein
composition, these granules likely vary in their specificity for RNA targets. Therefore
RVFV, and other bunyaviruses, may provide a useful tool for probing the RNA
composition of subsets of granules.
I profiled mRNA targets of RVFV in rapidly dividing cells. However, many
bunyaviruses replicate in senescent cells, such as neurons, and RVFV is neurotropic.
Interestingly, neurons possess specialized and extensive P body like structures termed
“neuronal granules” that have a similar protein content and function and provide spatial
regulation of translation (3). RNAs in these granules are sensitive to overexpression of
DCP1A and their expression may affect synaptic plasticity and cytoskeletal organization
(97). I hypothesize that neurotropic bunyaviruses use this pool of non-translating stored
mRNAs for cap-snatching, and this large pool of targets may explain efficient replication
in this cell type. Future studies will examine endogenously cap-snatched mRNA targets
in primary rat neurons.
To add further complexity, while Drosophila encode only one known decapper, in
mammals there are at least two decappers (DCP2 and NUDT16), possessing both
specific and redundant functions in mRNA decay pathways (76). This suggests a tight
degree of regulation in both the specificity of target selection to decapping enzymes,
which likely reside in distinct compartments, and decapping activation itself. I found that
both overlap and specificity exist in the mRNAs targeted by these decappers in human
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cells and their ability to restrict specific RVFV-host mRNA conjugates. While it has been
established that NUDT16 exists both in the nucleus and the cytoplasm, whether it
resides in P bodies or P-body-like punctae in the cytoplasm has not been described and
is partially hampered by a lack of endogenous antibodies. Preliminary data suggest that,
indeed, NUDT16 may exist in cytoplasmic punctae in the cytoplasm, at least in the
context of enforced expression (Figure 4.5E). Future work will examine whether these
punctae colocalize with known P body markers, such as DDX6 and DCP1a, DCP2 itself,
or the viral cap-snatching machinery. I hypothesize that partial overlap exists between all
of these compartments and that this spatial organization contributes to the specificity of
mRNAs targeted by viral cap-snatching and by decappers. Further work should elucidate
the regulation of RNA targeting to decapping enzyme compartments and their activation,
as these are potentially druggable proteins. The potential to induce decapping to restrict
bunyaviral infection through the decay of RNA targets is exciting, as no therapeutic
interventions currently exist for these infections. Additionally, my findings that cell cycle
mRNA stability is specifically sensitive to decapping in insects suggests the possibility
that decapping could be induced as a mechanism for restricting the expression of cell
cycle regulated genes during cell cycle disregulation, including cancer. While I have
shown that ribosomal and translation related mRNAs are primarily targeted for capsnatching by RVFV in humans, whether the basal levels of these RNAs are appreciably
affected by decapping in uninfected cells remains to be established. It is possible that
translation mRNAs are targeted specifically for decay through decapping activation as a
means to trigger translational shutdown; I hypothesize that this specificity is mediated
through targeted decay of TOP motif containing mRNAs. Whether the stability of
translation related mRNAs is decay dependent endogenously, or whether this occurs
only as a novel response to infection requires further investigation (Figure 5.2). Gene
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regulation and control are of the utmost importance in both research and disease, and
the technical advances achieved through the discovery of RNAi have revolutionized the
field. The discovery that multiple decappers exist with potential target specificity points to
new mechanisms for controlling gene programs by harnessing decapping to induce
specific cellular mRNA decay.
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Figure 5.1: Decapping and cap-snatching machinery compete for cell cycle regulated
mRNAs. Left: Schematic of P body dynamics during cell cycle progression. During G1, P bodies
(green) are present at low levels in cells. As cells exit S phase and progress into G2, P bodies
increase in number and size (61, 144). As cell enter mitosis, P bodies are lost (144). Upper
Inset: RVFV cap-snatching and Dcp2 mRNA decapping are competing processes. Viral mRNA
transcription initiates upon the binding of RVFV N (red circles) to 5’caps of cellular mRNAs (blue).
Next, RVFV L (red moons) is recruited and its endonuclease activity cleaves 10-18bp
downstream of the cap and uses this primer to initiate viral transcription from the genomic RNA
(black line), producing cellular-virus conjugate mRNAs (blue and red line). Dcp2 (orange) targets
and degrades the same pool of cellular mRNAs that RVFV uses for transcription, creating a
bottleneck. Lower Inset: During the S/G2 phase of the cell cycle, as mRNAs required for DNA
replication are targeted for degradation (blue), this increased level of substrates alleviates the
bottleneck, allowing the viral cap-snatching machinery to increase viral transcription (blue and red
lines). Thus, arresting cells in S/G2 increases bunyaviral replication.
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Figure 5.2: Decapping may restrict viral infection in humans through the decay of core
translation mRNAs. 1. During RVFV infection, the viral infection is sensed. 2. A signaling
cascade may potentially lead to the targeting of core translational mRNAs for decapping. 3.
Following targeting, core translation mRNAs are degraded. 4. Decay of host translation mRNAs
over time leads to loss of ribosome biogenesis and shutdown of host translation.
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Table 6.1. Validated hits from a genome-wide RNAi screen for genes impacting RVFV replication in Drosophila. Percent infection Z
scores of screen hits with human homolog names, Flybase IDs, and informatics based cellular categories. Genes with cell cycle GO terms,
S phase associated GO terms, or those that showed >30% increase in nuclear size (large nuclei) are indicated (n=2, p<0.05).

Flybase
Symbol

Human
Symbol

PRIMARY SCREEN %
INFECTION

SECONDARY SCREEN
% INFECTION

Z SCORE
1

Z SCORE
2

Z SCORE
1

Z SCORE
2

Flybase Gene
ID

Placement in Figure 3.2

Cell
Cycle
GO term

S phase
associated

Large
nuclei
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alphaCop

COPA

1.76

3.20

4.13

3.58

FBgn0025725

COPI

ATPsyn-beta
ATPsyngamma

ATP5B

1.37

2.37

6.30

5.55

FBgn0010217

Mitochondrial

ATP5C1

2.93

2.68

5.69

6.33

FBgn0020235

Mitochondrial

Bap60

SMARCD1

1.76

3.46

3.41

3.33

FBgn0025463

Transcription/Chromatin

beta'Cop

COPB2

2.24

2.93

2.76

3.77

FBgn0025724

COPI

betaCop

COPB1

1.83

2.69

7.00

6.72

FBgn0008635

COPI

Bx42

SNW1

3.44

2.04

4.05

4.76

FBgn0004856

Transcription/Chromatin

c12.1

CWC15

3.85

1.45

3.49

4.50

FBgn0040235

Splicing

cdc2

CDK1

2.64

2.93

5.51

6.35

FBgn0004106

Cell Cycle

X

X

CG10754

SF3A2

2.16

1.72

5.74

5.52

FBgn0036314

Splicing

X

X

CG11583

BRIX1

1.59

4.88

3.79

4.92

FBgn0035524

Ribosome Biogenesis

2.39

1.53

1.50

1.51

FBgn0036584

Other

FBgn0032050

Ribosome

CG13054
CG13096

RSL1D1

1.58

3.06

CG1311

SLC44A1

1.59

4.88

3.86

3.20

FBgn0035523

Membrane

1.90

1.38

1.70

1.99

FBgn0035582

Other

1.96

1.64

1.40

2.45

FBgn0029915

Other

1.89

1.64

5.55

5.50

FBgn0037220

Splicing

1.42

3.74

1.55

1.31

FBgn0037317

Nucleic Acid Binding

CG13705
CG14434
CG14641

RBM22

CG14667

Ribosome

CG15220

RPA3

1.68

2.14

3.74

4.37

FBgn0030322

Cell Cycle

CG1542

EBNA1BP2

1.74

4.10

4.24

5.27

FBgn0039828

Cell Cycle

CG16903

CCNL1

2.50

3.82

6.27

4.56

FBgn0040394

Cell Cycle

CG16941

SF3A1

2.88

2.37

4.99

4.48

FBgn0038464

Splicing

X

X

X

X
X

CG1746

ATP5G2

CG18577

2.36

3.04

3.21

3.46

FBgn0039830

Mitochondrial

1.31

1.32

1.93

2.25

FBgn0037870

Other
Splicing

CG2063

SAP30BP

1.58

4.43

5.48

5.40

FBgn0033400

CG3224

ZNF593

4.69

1.92

3.39

3.39

FBgn0029885

Nucleic Acid Binding

CG32808

KLK7

1.61

4.29

2.75

2.88

FBgn0052808

Protein Modifications

CG40127

RNASEK

-2.01

-1.61

-5.14

-7.43

FBgn0262116

RNA decay

CG4849

EFTUD2

4.78

2.87

6.78

5.86

FBgn0039566

Splicing

CG6841

PRPF6

1.93

3.82

4.43

4.84

FBgn0036828

Splicing

1.37

2.23

1.76

1.46

FBgn0030961

Other

CG7058
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CG7675

RDH14

1.66

1.55

3.50

1.37

FBgn0038610

Metabolism

CG8097

DALRD3

1.32

1.50

1.77

1.71

FBgn0030660

Translation

CG8108

CIZ1

2.26

1.96

2.03

1.83

FBgn0027567

Cell Cycle

CG8636

EIF3G

2.60

3.89

5.40

5.39

FBgn0029629

Translation

CG8801

GTPBP4

1.93

3.29

3.38

4.32

FBgn0028473

Ribosome Biogenesis

CG9667

ISY1

2.87

3.18

5.71

4.98

FBgn0037550

Splicing

CG9715

2.29

3.04

3.53

3.38

FBgn0036668

Nucleic Acid Binding

Chro

1.45

2.87

2.01

2.69

FBgn0044324

Cell Cycle

X

X
X

X

CycA

CCNA1

2.29

3.56

9.35

9.50

FBgn0000404

Cell Cycle

Dcp2

DCP2

2.12

3.52

4.57

5.08

FBgn0036534

RNA decay

deltaCOP

ARCN1

1.95

2.89

FBgn0028969

COPI

Dis3

DIS3

1.52

3.35

5.04

4.56

FBgn0039183

RNA decay

DMAP1

DMAP1

1.49

2.34

3.47

4.01

FBgn0034537

Transcription/Chromatin

X

E2f

E2F3

1.97

2.51

2.43

2.16

FBgn0011766

Transcription/Chromatin

X

eIF-3p66

EIF3D

1.69

3.79

6.02

7.05

FBgn0040227

Translation

eIF2B-beta

EIF2B2

1.33

1.73

4.51

5.80

FBgn0024996

Translation

gammaCop

COPG

2.15

3.03

FBgn0028968

COPI

geminin

GMNN

2.50

4.96

FBgn0033081

Cell Cycle

COPI Transport

COPI Transport
8.27

7.98

X

X

X

X

X

X
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His3:CG31613

HIST2H3C

2.60

1.85

2.78

3.45

FBgn0051613

Cell Cycle

X

His4:CG31611

HIST1H4B

1.52

1.95

3.55

3.97

FBgn0051611

Cell Cycle

X

hoip

NHP2L1

2.27

3.63

5.77

6.26

FBgn0015393

Splicing

l(1)1Bi

MYBBP1A

2.26

1.81

2.50

2.67

FBgn0001341

Ribosome Biogenesis

l(2)37Cc

PHB

1.60

2.66

4.41

5.20

FBgn0002031

Mitochondrial

LSm7

LSM7

1.36

1.96

5.27

5.12

FBgn0261068

RNA decay

me31B

DDX6

2.01

3.54

5.74

6.41

FBgn0004419

RNA decay

mRpL27

MRPL27

2.29

3.84

FBgn0053002

Mitochondrial

mts

PPP2CB

2.36

1.68

5.08

4.54

FBgn0004177

Cell Cycle

nej

EP300

1.89

4.13

4.68

4.37

FBgn0261617

Cell Cycle

Nmt

NMT1

1.43

1.40

3.92

4.94

FBgn0020392

Protein Modifications

ns1

GNL3L

2.27

5.19

4.13

5.51

FBgn0038473

Ribosome Biogenesis

Nup62

NUP62

2.14

3.58

5.95

5.50

FBgn0034118

Nuclear Pore

Pp4-19C

PPP4C

2.22

2.69

3.72

3.27

FBgn0023177

Cell Cycle

X

Pros25

PSMA2

-2.14

-2.22

-6.46

-7.40

FBgn0086134

Proteasome

X

Pros26

PSMB1

-3.92

-3.20

-7.51

-5.11

FBgn0034118

Proteasome

Prosbeta3

PSMB3

-2.81

-2.13

-4.41

-6.34

FBgn0026380

Proteasome

Prosbeta5

PSMB5

-1.91

-2.01

FBgn0029134

Proteasome

Prp18

PRPF18

1.53

2.87

FBgn0027784

Splicing

qm

RPL10

2.21

3.64

FBgn0019662

Ribosome

Rab5

RAB5A

-2.96

-3.18

-3.84

-3.50

FBgn0014010

Trafficking

X

Rbm13

MAK16

2.11

4.15

3.23

3.34

FBgn0030067

Ribosome Biogenesis

X

1.83

4.73

6.56

4.91

FBgn0017551

Cell Cycle

X

Rca1

Ribosome

Proteasome
4.44

4.89

Ribosome

RnrS

RRM2

1.61

1.30

5.13

5.49

FBgn0011704

Cell Cycle

RpA-70

RPA1

1.70

2.78

5.56

5.71

FBgn0010173

Cell Cycle

RPA2

RPA2

1.74
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